WO2022249152A2 - Cas13-based compositions and methods of use thereof - Google Patents
Cas13-based compositions and methods of use thereof Download PDFInfo
- Publication number
- WO2022249152A2 WO2022249152A2 PCT/IB2022/055036 IB2022055036W WO2022249152A2 WO 2022249152 A2 WO2022249152 A2 WO 2022249152A2 IB 2022055036 W IB2022055036 W IB 2022055036W WO 2022249152 A2 WO2022249152 A2 WO 2022249152A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- rna
- cas13
- seq
- crrna
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 134
- 239000000203 mixture Substances 0.000 title claims description 97
- 238000001514 detection method Methods 0.000 claims description 327
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 324
- 108090000623 proteins and genes Proteins 0.000 claims description 296
- 102000004169 proteins and genes Human genes 0.000 claims description 266
- 210000004027 cell Anatomy 0.000 claims description 124
- 150000007523 nucleic acids Chemical class 0.000 claims description 117
- 102000039446 nucleic acids Human genes 0.000 claims description 107
- 108020004707 nucleic acids Proteins 0.000 claims description 107
- 238000003776 cleavage reaction Methods 0.000 claims description 98
- 230000007017 scission Effects 0.000 claims description 91
- 239000012636 effector Substances 0.000 claims description 85
- 239000002773 nucleotide Substances 0.000 claims description 69
- 125000003729 nucleotide group Chemical group 0.000 claims description 69
- 230000014509 gene expression Effects 0.000 claims description 61
- 239000013598 vector Substances 0.000 claims description 61
- 125000006850 spacer group Chemical group 0.000 claims description 60
- 108020004414 DNA Proteins 0.000 claims description 54
- 238000013518 transcription Methods 0.000 claims description 48
- 230000035897 transcription Effects 0.000 claims description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 41
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 41
- 102000040430 polynucleotide Human genes 0.000 claims description 41
- 108091033319 polynucleotide Proteins 0.000 claims description 41
- 239000002157 polynucleotide Substances 0.000 claims description 40
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 36
- 108091034117 Oligonucleotide Proteins 0.000 claims description 34
- 238000011901 isothermal amplification Methods 0.000 claims description 29
- 241000894006 Bacteria Species 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 21
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 20
- 102000053602 DNA Human genes 0.000 claims description 19
- 108020004705 Codon Proteins 0.000 claims description 17
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 17
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 16
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 238000010839 reverse transcription Methods 0.000 claims description 12
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 claims description 11
- 230000001419 dependent effect Effects 0.000 claims description 10
- 108010021843 fluorescent protein 583 Proteins 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 10
- 230000004807 localization Effects 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 claims description 7
- 101000686486 Homo sapiens Double-stranded RNA-specific editase B2 Proteins 0.000 claims description 7
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 6
- 241000206602 Eukaryota Species 0.000 claims description 6
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 230000000536 complexating effect Effects 0.000 claims description 5
- 241001515965 unidentified phage Species 0.000 claims description 5
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 claims description 4
- 102100024692 Double-stranded RNA-specific editase B2 Human genes 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 108700005077 Viral Genes Proteins 0.000 claims description 4
- 241001135756 Alphaproteobacteria Species 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 description 242
- 108091079001 CRISPR RNA Proteins 0.000 description 194
- 238000006243 chemical reaction Methods 0.000 description 182
- 230000000694 effects Effects 0.000 description 140
- 238000003556 assay Methods 0.000 description 129
- 239000013615 primer Substances 0.000 description 119
- 238000005580 one pot reaction Methods 0.000 description 80
- 101000860096 Herbinix hemicellulosilytica CRISPR-associated endoribonuclease Cas13a Proteins 0.000 description 73
- 102000004190 Enzymes Human genes 0.000 description 63
- 108090000790 Enzymes Proteins 0.000 description 63
- 229940088598 enzyme Drugs 0.000 description 63
- 239000000523 sample Substances 0.000 description 61
- 238000000338 in vitro Methods 0.000 description 54
- 238000012360 testing method Methods 0.000 description 44
- 241000700605 Viruses Species 0.000 description 43
- 238000007397 LAMP assay Methods 0.000 description 42
- 230000003321 amplification Effects 0.000 description 42
- 238000003199 nucleic acid amplification method Methods 0.000 description 42
- 230000008685 targeting Effects 0.000 description 37
- 108090000621 Ribonuclease P Proteins 0.000 description 35
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 34
- 102000004167 Ribonuclease P Human genes 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- 230000004048 modification Effects 0.000 description 32
- 238000012986 modification Methods 0.000 description 32
- 239000000047 product Substances 0.000 description 29
- 208000025721 COVID-19 Diseases 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 238000011529 RT qPCR Methods 0.000 description 27
- 239000000872 buffer Substances 0.000 description 26
- 239000013604 expression vector Substances 0.000 description 26
- 230000001404 mediated effect Effects 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 238000012545 processing Methods 0.000 description 25
- 238000012216 screening Methods 0.000 description 25
- 230000035945 sensitivity Effects 0.000 description 25
- 238000003752 polymerase chain reaction Methods 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 230000000007 visual effect Effects 0.000 description 21
- 238000000605 extraction Methods 0.000 description 20
- 238000011161 development Methods 0.000 description 19
- 230000018109 developmental process Effects 0.000 description 19
- 241000494545 Cordyline virus 2 Species 0.000 description 18
- 230000008901 benefit Effects 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 18
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 17
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000003197 gene knockdown Methods 0.000 description 17
- 101710163270 Nuclease Proteins 0.000 description 16
- 101100240079 Severe acute respiratory syndrome coronavirus 2 N gene Proteins 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000003197 catalytic effect Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 238000012512 characterization method Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 108091093088 Amplicon Proteins 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 12
- 108020005004 Guide RNA Proteins 0.000 description 12
- 238000002123 RNA extraction Methods 0.000 description 12
- 101710137500 T7 RNA polymerase Proteins 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 238000011896 sensitive detection Methods 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 10
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 10
- 102100031780 Endonuclease Human genes 0.000 description 10
- 101000860104 Leptotrichia wadei (strain F0279) CRISPR-associated endoribonuclease Cas13a Proteins 0.000 description 10
- 230000026279 RNA modification Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000702308 Tomato yellow leaf curl virus Species 0.000 description 10
- 238000012549 training Methods 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 241000711549 Hepacivirus C Species 0.000 description 9
- 238000010357 RNA editing Methods 0.000 description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000012864 cross contamination Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 102000006382 Ribonucleases Human genes 0.000 description 8
- 108010083644 Ribonucleases Proteins 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 241001493065 dsRNA viruses Species 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000011895 specific detection Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000013614 RNA sample Substances 0.000 description 7
- 238000002869 basic local alignment search tool Methods 0.000 description 7
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 6
- 241000702421 Dependoparvovirus Species 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 6
- 108020000999 Viral RNA Proteins 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000013135 deep learning Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 101710159080 Aconitate hydratase A Proteins 0.000 description 5
- 101710159078 Aconitate hydratase B Proteins 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 5
- 108700004991 Cas12a Proteins 0.000 description 5
- 241000450599 DNA viruses Species 0.000 description 5
- 241000613556 Herbinix hemicellulosilytica Species 0.000 description 5
- 101710105008 RNA-binding protein Proteins 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 241000723873 Tobacco mosaic virus Species 0.000 description 5
- 101150063416 add gene Proteins 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108700010070 Codon Usage Proteins 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 4
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000192142 Proteobacteria Species 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 241000723838 Turnip mosaic virus Species 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000025608 mitochondrion localization Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 morpholino nucleic acids Chemical class 0.000 description 4
- 238000012803 optimization experiment Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 239000013607 AAV vector Substances 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000007022 RNA scission Effects 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 102000043770 human ADAR Human genes 0.000 description 3
- 102000044898 human ADARB1 Human genes 0.000 description 3
- 102000051729 human ADARB2 Human genes 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000003161 ribonuclease inhibitor Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100026846 Cytidine deaminase Human genes 0.000 description 2
- 108010031325 Cytidine deaminase Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091028113 Trans-activating crRNA Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000013527 convolutional neural network Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000013504 emergency use authorization Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000001293 nucleolytic effect Effects 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000003094 perturbing effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 2
- 230000006648 viral gene expression Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- KCYOZNARADAZIZ-CWBQGUJCSA-N 2-[(2e,4e,6e,8e,10e,12e,14e)-15-(4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl)-6,11-dimethylhexadeca-2,4,6,8,10,12,14-heptaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol Chemical compound O1C2(C)CC(O)CC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C1C=C2C(C)(C)CCCC2(C)O1 KCYOZNARADAZIZ-CWBQGUJCSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 description 1
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 108700040115 Adenosine deaminases Proteins 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241001063273 Alicyclobacillus acidiphilus Species 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000175213 Alloherpesviridae Species 0.000 description 1
- 241001206546 Ampullaviridae Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000157873 Ascoviridae Species 0.000 description 1
- 241000977261 Asfarviridae Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000724653 Borna disease virus Species 0.000 description 1
- 241000776207 Bornaviridae Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 241000351651 Clavaviridae Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 102100021864 Cocaine esterase Human genes 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000701520 Corticoviridae Species 0.000 description 1
- 241000158508 Corynebacterium amycolatum Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- KCYOZNARADAZIZ-PPBBKLJYSA-N Cryptochrome Natural products O[C@@H]1CC(C)(C)C=2[C@@](C)(O[C@H](/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(\C)/[C@H]3O[C@@]4(C)C(C(C)(C)CCC4)=C3)/C)\C)/C)C=2)C1 KCYOZNARADAZIZ-PPBBKLJYSA-N 0.000 description 1
- 108010037139 Cryptochromes Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241001533413 Deltavirus Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000351109 Dinodnavirus Species 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000701367 Fuselloviridae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001136687 Globuloviridae Species 0.000 description 1
- 241001664989 Guttaviridae Species 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 241000543391 Hytrosaviridae Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000401051 Influenza D virus Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000029603 Leptotrichia shahii Species 0.000 description 1
- 241000701365 Lipothrixviridae Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 101100385364 Listeria seeligeri serovar 1/2b (strain ATCC 35967 / DSM 20751 / CCM 3970 / CIP 100100 / NCTC 11856 / SLCC 3954 / 1120) cas13 gene Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000186187 Mimiviridae Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001484257 Nimaviridae Species 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 241000405453 Nudiviridae Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001647379 Parachlamydia Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000701253 Phycodnaviridae Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108020005120 Plant DNA Proteins 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 241000701369 Plasmaviridae Species 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 241000702072 Podoviridae Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001631648 Polyomaviridae Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 230000014632 RNA localization Effects 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000040592 Rudiviridae Species 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241001053778 Salterprovirus Species 0.000 description 1
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000702202 Siphoviridae Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241001514388 Sphaerolipoviridae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 102100035726 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 241000701521 Tectiviridae Species 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 210000002378 Th9 Anatomy 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000405439 Turriviridae Species 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000194314 Vibrio cholerae O139 Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000696962 White spot syndrome virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KCYOZNARADAZIZ-XZOHMNSDSA-N beta-cryptochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C3OC4(C)CCCC(C)(C)C4=C3 KCYOZNARADAZIZ-XZOHMNSDSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 108010064410 ***e esterase Proteins 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-O diphenylphosphanium Chemical compound C=1C=CC=CC=1[PH2+]C1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-O 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000005496 phosphonium group Chemical group 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000010340 saliva test Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000037423 splicing regulation Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000013526 transfer learning Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Definitions
- SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2019
- Coronaviridae family that represents positive-stranded RNA viruses with some of the largest known RNA genomes [1].
- Members of this family pose a continuous threat to the global community due to their propensity for causing disease outbreaks as witnessed for the third time in the 21 st century. Rapid mutation in their genomic RNA along with frequent recombination events facilitates inter- species transmission that often leads to unexpected and uncontrollable epidemic outbreaks.
- the Cas12 and Cas13 enzymes complex with their corresponding single-guide RNA (sgRNA) and scan a DNA or RNA template for a complementary sequence. Once a complementary sequence is recognized, the enzyme cleaves the nucleic acid in cis and, once activated by the initial recognition, exhibits collateral trans cleavage activities, cleaving single-stranded (ss) DNA or RNA molecules present in the reaction [39, 40].
- This collateral cleavage activity of Cas12 and Cas13 has been harnessed for nucleic acid detection.
- the CRISPR-Cas13 system coupled with RPA was used for virus detection via SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) [41-43].
- HUDSON Heating Unextracted Diagnostic Samples to Obliterate Nucleases
- SHERLOCK SHERLOCK
- isothermal amplification methods such as recombinase polymerase amplification (RPA) or loop-mediated isothermal amplification (LAMP)
- CRISPR/Cas detection assays facilitate target nucleic acid detection at attomolar levels [6, 7].
- RPA recombinase polymerase amplification
- LAMP loop-mediated isothermal amplification
- compositions and methods of use thereof are disclosed.
- the compositions and methods are especially applicable to rapid and facile detection of nucleic acids, perturbation of gene expression and RNA modification.
- a polynucleotide containing a nucleotide sequence encoding a class II, type VI CRISPR/Cas effector protein (Cas13) and optionally including a heterologous sequence is disclosed.
- the Cas effector protein includes the amino acid sequence encoded by SEQ ID NO:63, SEQ ID NO:65, or SEQ ID NO:67 (i.e., SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68), or a sequence with at least 70% sequence identity thereto.
- the sequence encoding the Cas effector protein is or includes SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67, or a sequence with at least 70% sequence identity to SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67.
- the nucleotide sequence does not include SEQ ID NO:63, 65 or 67.
- the nucleotide sequence does not include SEQ ID NO:63, 65 or 67 even when it encodes the same protein encoded by SEQ ID NO:63, 65 or 67.
- the sequence encoding the Cas effector protein is codon optimized for expression in a prokaryotic or eukaryotic cell.
- the heterologous sequence can be, for example, an expression control sequence, and can include a promoter, transcription terminator, multiple cloning site, drug resistance marker(s), one or more protease recognition sites, one or more epitope tags, or a combination thereof.
- the heterologous sequence is operably linked to the sequence encoding the Cas effector protein.
- the polynucleotide further includes a sequence encoding a crRNA.
- the crRNA is capable of complexing with the Cas effector protein and hybridizing to a target RNA sequence.
- the Cas effector protein can originate or be derived from Thermoclostridium caenicola or a Proteobacteria bacterium.
- the polynucleotide is or is contained in a vector, such as an expression vector.
- suitable vectors include viral vectors or plasmids.
- Cells harboring the polynucleotides and/or vectors are also provided.
- prokaryotic or eukaryotic cells containing the polynucleotide and/or vector are disclosed.
- methods of producing a class II, type VI CRISPR/Cas effector protein involves introducing the disclosed vector into a prokaryotic or eukaryotic cell under conditions suitable for expression of the sequence encoding the Cas effector protein.
- the method further involves isolating and/or purifying the Cas effector protein.
- Isolated class II, type VI CRISPR/Cas effector proteins produced by the foregoing method are also provided.
- disclosed is an isolated class II, type VI CRISPR/Cas effector protein having the amino acid sequence of SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68, or a sequence with at least 70% sequence identity to SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68.
- the Cas effector protein is associated with a crRNA.
- compositions including a Cas13 protein having or including the amino acid sequence of SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68, or a sequence with at least 70% sequence identity to SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68.
- the Cas13 protein contains one or more Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) domains, preferably two HEPN domains.
- HEPN Higher Eukaryotes and Prokaryotes Nucleotide-binding
- an exemplary HEPN domain is a RxxxxH (SEQ ID NO:192) motif sequence, wherein X represents any amino acid.
- the Cas13 protein is complexed with a crRNA, which optionally, but not necessarily, is capable of hybridizing to a target RNA sequence.
- the crRNA can include a spacer sequence that is capable of hybridizing to the target RNA sequence and a direct repeat sequence.
- the crRNA comprises a spacer of about 20- 30 nucleotides, preferably 24-28 nucleotides.
- the Cas13 protein can cleave the target RNA sequence at a temperature of about 37-70 o C, about 50-70 o C, about 47-60 o C, or about 60 oC. In some embodiments, the Cas13 protein can cleave the target RNA sequence at a temperature of about 37 o C-42 °C, preferably about 37 o C.
- the composition may be present in a cell, such as a prokaryotic or eukaryotic cell. Methods of using the disclosed polynucleotides, vectors, proteins, protein complexes, and compositions are also provided.
- RNA transcript can be any ssRNA sequence including coding (e.g., an mRNA) or non-coding (e.g., lincRNA) RNA.
- coding e.g., an mRNA
- non-coding e.g., lincRNA
- the RNA transcript is derived from a viral gene, such as a bacteriophage.
- the compositions can be used in methods of inhibiting viral gene expression or viral replication. Methods of using the compositions to detect target nucleic acids are also provided.
- RNA transcript in a nucleic acid sample by contacting the sample with the Cas13 composition in the presence of an activatable single stranded RNA (ssRNA) oligonucleotide that includes a reporter moiety.
- the reporter moiety includes a fluorophore linked to a quencher via the ssRNA. Fluorescence can be emitted upon cleavage of the ssRNA oligonucleotide since the quencher is no longer in proximity to the fluorophore.
- the crRNA is designed to hybridize to the RNA transcript and the Cas13 cleaves the ssRNA oligonucleotide upon binding of the Cas13 crRNA complex to the RNA transcript. Detecting cleavage of the ssRNA oligonucleotide indicates the presence of the RNA transcript.
- the RNA transcript could have been generated by transcription from a dsDNA molecule, and in some embodiments, the dsDNA molecule could have been generated by reverse transcription coupled (isothermal) amplification of a target RNA.
- Methods of monitoring RNA trafficking are also provided. For example, described herein is a method of determining the localization of an RNA transcript in a cell by introducing the Cas13 composition to the cell.
- the Cas13 is preferably catalytically inactive (e.g., the Cas13 functions as an RNA binding protein without nuclease activity).
- the Cas13 preferably further includes a detectable marker.
- the crRNA is designed to hybridize to the RNA transcript, and the Cas13 crRNA complex binds to the RNA transcript, thereby indicating the location of the RNA transcript.
- Exemplary detectable markers include GFP, eGFP, RFP, YFP, BFP, CFP, mNeonGreen, mCherry, mOrange, mRaspberry, mPlum, mKO, mRFP, mRFPruby, mRuby, tagRFP, mKate2, and DsRed. Also disclosed is a method for performing targeted editing of an RNA transcript by introducing a composition of a catalytically inactive Cas13 that further includes a deaminase domain of an RNA-dependent Adenosine Deaminase (ADAR) to a cell.
- ADAR RNA-dependent Adenosine Deaminase
- the crRNA complexed to the Cas13 is capable of hybridizing with a region in the RNA transcript that contains an A nucleotide to be edited.
- the crRNA forms an RNA duplex with the RNA transcript that contains an A-C mismatch at the target A nucleotide resulting in the target A nucleotide being deaminated by the deaminase domain (resulting in A-I).
- Suitable deaminase domains include deaminase domains from ADAR1, ADAR2, and ADAR3, such as human ADAR1, ADAR2, and ADAR3. Additional advantages of the disclosed methods and compositions will be set forth in part in the description which follows, and in part will be understood from the description, or can be learned by practice of the disclosed methods and compositions.
- FIG. 1C is a maximum-likelihood phylogenetic tree of Cas13 proteins from different organisms. The tree was generated using MEGA X software. Most selected proteins were isolated from mesophilic bacteria, although several have been cultivated as thermophiles, and thus offer an interesting collection of high-temperature stable proteins. TccCas13a and HheCas13a were selected as potentially thermophilic Cas13 proteins.
- Figure 1D is a series of plots showing differential scanning fluorimetry (DSF) profiles of protein melting point using a conventional real-time PCR instrument.
- the peak in the left graph indicates protein denaturation.
- the right- side graph is the derivative of the left-side graph.
- Figure 1F is a heat map showing TccCas13a collateral cleavage preference for the ssRNA reporter.
- Reactions consisting of TccCas13a and its respective cognate crRNAs or non-specific crRNA (NS) control were performed in the presence of ssRNA target and one of ten ssRNA reporters.
- ssRNA reporter sequences are shown on top of the heatmap.
- Figure 1G is a heat map showing HheCas13a collateral cleavage preference for the ssRNA reporter.
- Reactions consisting of HheCas13a and its respective cognate crRNAs or non-specific crRNA (NS) control were performed in the presence of ssRNA target and one of six ssRNA reporters.
- NS non-specific crRNA.
- ssRNA reporter sequences are shown on top of the panel, A: Poly A reporter, U: Poly U reporter, G: Poly 6G reporter, UG: 3(UG) reporter, CG: 3(CG) reporter, Mix: Mix reporter.
- Figures 2A-2B are graphs showing the in-trans activity of HheCas13a and TccCas13a assessed at varying target concentrations and two different temperatures.
- Figure 2D is a bar graph showing the in-trans activity of TccCas13a assessed at 60 °C with two crRNAs of different spacer lengths targeting the N SARS-CoV-2 gene and one non-specific (NS) crRNA.
- FIG. 2E is a plot showing end-point activity of LwaCas13a, HheCas13a and TccCas13a at different temperatures using their preferred reporter. One crRNA and a non-specific crRNA were tested for each. Values are shown as mean ⁇ S.D and represent endpoint fluorescence at 30 min.
- Figure 2F is predicted secondary RNA structure of the direct repeat sequence of TccCas13a crRNA. RNAfold ran.tbi.univie.ac.at/ was used to predict the crRNA secondary structure.
- Figures 3A-3D are bar graphs showing the results of the screening of the indicated HheCas13a and TccCas13a crRNAs paired with various primers in the two-pot assay.
- RT- LAMP amplification was performed first and the RT-LAMP product was added to the T7-in vitro transcription and Cas13-based detection reaction (two-pots).
- FIGS. 4A-4D are bar graphs showing the results of the screening of the indicated HheCas13a and TccCas13a crRNAs paired with various primers in the one-pot assay.
- SC STOPCovid
- RT- LAMP amplification T7-in vitro transcription and Cas13-based detection was performed in single step at single temperature, 55 °C (one-pot).
- Figures 5A-5E are graphs showing the results from a second round of screening of the indicated HheCas13a and TccCas13a crRNAs and different primer sets for the establishment of one-pot assay.
- RT-LAMP amplification T7-in vitro transcription and Cas13-based detection was performed in single step at single temperature, 55 °C (one-pot).
- NS non- specific crRNA. Reactions were run for 80 mins.
- Figure 6 is a heatmap showing the in-trans activity of the one-pot detection assay with synthetic RNA using different Bst DNA polymerases from different vendors.
- Figures 7A-7D are bar graphs showing the cleavage activity towards the reporter probe in the one-pot assay with different concentrations of Bst DNA polymerase (Fig.7A), MgSO4 (Fig.7B), Hi-T7 RNA polymerase (Fig. 7C), and TccCas13a and crRNA (RNP) concentrations (Fig.7D).
- NTC non- template control.
- Figure 9 is a graph quantifying the performance of the thermophilic Cas13-based one-pot detection assay on SARS-CoV-2 patient samples. RNA extracted from clinical samples from 8 patients with SARS-CoV-2 infection (Table 6) were analyzed with the one-pot detection assay. NTC: no template control.
- Figure 10A is a schematic of specific Cas13-based detection. Specific target recognition by Cas13 RNP triggers non-specific, collateral activity that cleaves the reporters, resulting in a detectable fluorescent signal.
- Figures 10B-10F are bar graphs showing cleavage activity across various reporter and crRNA sequences. Reactions containing mCas13 and four different crRNAs targeting the SARS-CoV-2 N gene or non-specific crRNA (NS) control were performed in the presence of one of five reporters. F- NNNNN-Q represents the RNaseAlert v2 reporter (Thermofisher). NS: non- specific (not targeting SARS-CoV-2) crRNA.
- Figure 10G is a bar graph quantifying the effect of mismatches between mCas13 crRNA and target RNA on mCas13 activity. Left, crRNA nucleotide sequence with the positions of mismatches (red) on the crRNA. Right, the fluorescence intensity, relative to the no-template control (NTC, gray) or crRNA with no mismatches (purple), resulting from mCas13 collateral cleavage activity on each tested crRNA.
- Figure 10H is a schematic illustration of the sequence similarity searching strategies for the identification of miniature Cas13 effectors. BLASTp analysis was performed before January 2021.
- Figure 10K shows multiple sequence alignment of mCas13 and compact Cas13e and Cas13f orthologues. Protein sequences of mCas13, Cas13e.1, Cas13e.2, Cas13f.1, Cas13f.2, Cas13f.3, Cas13f.4 and Cas13f.5 were aligned using ClustalW in MEGAX and ESPript was used to generate the alignment visualization. Strictly conserved residues (%Strict) are shown in red text within blue rectangles. conserveed RxxxxH (SEQ ID NO:192) motifs of the HEPN domains are highlighted with yellow background. Figure 10L a bar graph showing activity assessment of mCas13 with different crRNA sequences.
- Figure 10M is an illustration of the sequence of crRNA 4 and the position of synthetically introduced single mismatches.
- FIG 11A is a schematic of assay workflow of mCas13-based detection. Following sample collection and RNA extraction, pathogen RNA is reverse transcribed and amplified via RT-LAMP isothermal reaction. RT- LAMP primer sets (in which the FIP contains a T7 promoter sequence) are used, resulting in amplicons containing the T7-promoter sequence, which serve as templates for in vitro transcription of target RNA. Upon target recognition, mCas13 cleaves specially designed reporters in trans, leading to fluorescent signal output.
- Figure 11B is a graph showing measurement of real time fluorescence output of T7-mediated in vitro transcription and mCas13-based detection.
- Synthetic SARS-CoV-2 RNA was reverse transcribed and LAMP amplified with STOPCovid (SC) and DETECTR (DT) primer sets.
- crRNA 4 targeting crRNA # 4 identified in Figure 10.
- Figure 12A is a graph showing validation of mCas13-based detection assay on RT-qPCR–validated SARS-CoV-2 clinical samples with different Ct values. Pink bars represent mCas13-based detection fluorescence output.
- FAM RNA reporter labeled with FAM fluorophore used in mCas13 detection assays.
- FIG. 12B is a schematic representation of mCas13-based visual detection with a handheld fluorescence visualizer.
- Figures 12C-12D are images showing visual readouts of the limit of detection (LoD) of mCas13-based detection assay. LoD was determined using synthetic SARS-CoV-2 RNA (Fig.12C) or RT- qPCR-validated SARS-CoV-2 clinical samples with different Ct values (Fig. 12D), which were reverse transcribed and LAMP-amplified with the STOPCovid primer set. LAMP product was used for T7 in vitro transcription and concurrent mCas13 detection.
- Figure 12E is a series of images showing RT-LAMP mCas13 visual detection reactions of 24 SARS-CoV-2 RT-qPCR positive samples and no template control (NTC) reactions used to generate the heatmap in Fig.12F.
- NTC template control
- Figure 12F is a heat map displaying the validation of the mCas13-based visual detection assay of 24 SARS-CoV-2 RT-qPCR positive samples.
- RFU random fluorescence units, showing the signal intensity that was obtained by the TECAN plate reader for the mCas13 reactions.
- Figure 12G is an image showing fluorescent reporter (HEX reporter) concentration for clear visual detection of mCas13 collateral activity.
- mCas13 was incubated with crRNA 4 or non-specific (NS) crRNA and 100 nM of in vitro transcribed RNA of SARS- CoV-2 N gene using different concentrations of RNA reporter molecule with the sequence UUAUU that is conjugated to 5’ HEX for 45 mins. Reactions were visualized with p51 fluorescence visualizer and photo was taken with a smart phone.
- Figure 12H is an image showing a different repeat of the experiment done in Figure 3D. Picture was taken with different smart phone used in the other figures.
- NTC non-template control.
- Figures 12I and 12J are images of RT-LAMP mCas13 visual detection reactions of 24 SARS-CoV-2 RT-qPCR positive samples and no template control (NTC) reactions used to generate the heatmap in Figure 12F.
- Figure 12I shows reaction tubes with fluorescence readouts are shown with the clinical sample ID.
- Figure 12J reaction tubes withfluorescence readouts are shown with RT-qPCR Ct values indicated.
- Figure 13 is schematic illustrating identification of mCas13 and development of its use in a nucleic acid detection assay.
- Figures 14A-14D show In vitro characterization of thermostable Cas13a crRNAs sequence requirements.
- Figure 14F-14I are plots showing: 14F) single mismatches; 14G) double mismatches; 14H) 4 mismatches; 14I) crRNA spacer truncations.
- Left crRNA nucleotide sequence with the positions of mismatches on the crRNA spacer.
- Right the fluorescence intensity, relative to the non-specific crRNA control (NS) or crRNA with no mismatches, resulting from HheCas13a collateral cleavage activity on each tested crRNA. Reactions were incubated at 56 °C and endpoint fluorescence signal detection was measured after 30 min. Values are shown as mean ⁇ S.D.
- Figures 15A-15D illustrate exemplary one-pot SARS-CoV-2 detection using the thermophilic TccCas13a protein.
- Figure 15A is a schematic representation of the SARS-CoV-2 genome showing the region targeted by RT- LAMP amplification and the crRNA target sequence. The small arrow on the T7-FIP primer indicates the T7 promoter sequence. SC region: genomic region of SARS-CoV-2 N gene targeted with STOPCovid primers.
- Figure 15B is an overview of an exemplary assay workflow. The detection protocol includes three distinct steps, all carried out in the same tube and at the same temperature (56°C).
- RNA transcripts that are recognized and targeted simultaneously by the thermophilic TccCas13a protein.
- Recognition of the RNA transcripts by TccCas13a triggers Cas13 collateral cleavage activity, resulting in trans-cleavage of the reporter probe conjugated to the HEX or FAM fluorophores.
- Figures 16A-16D illustrate evaluation of OPTIMA-dx for the detection of SARS-CoV-2.
- Figure 16A a schematic representation of SARS-CoV-2 RNA detection in one-pot assays and visual detection using the P51 Molecular Fluorescence Viewer.
- Figure 16B is a series of images showing assessment of the sensitivity of OPTIMA-dx and the effect of reaction incubation time on performance using fluorescence-based visual detection. Fluorescence rises above background after 45 min with little improvement as time increases. Three replicates were performed for each treatment.
- Figure 16C is a plot showing SARS-CoV-2 detection from 100 clinical COVID-19 samples with one-pot RT-LAMP- TccCas13a detection assay.
- Figure 16D is a plot showing detection of RNase P internal control with one-pot RT-LAMP- TccCas13a detection assay. All 100 clinical samples in Fig.16A were tested for the detection of RNase P gene. Detection reactions were incubated at 56°C and the endpoint fluorescent signal was measured after 1 hour. NTC: no template control.
- Figures 17A-17D illustrate multiplexed OPTIMA-dx detection with TccCas13a and AapCas12b thermostable Cas enzymes.
- Figure 17A is a schematic representation of one-pot multiplexed OPTIMA-dx detection reaction.
- the unique collateral activity of Cas12 and Cas13 orthologues enables the use of different reporter molecules with different fluorophore, RNA reporter with FAM fluorophore for Cas13 and DNA reporter with HEX fluorophore for Cas12, and multi-channel detection.
- Figure 17C is a bar graph showing multiplexed detection of SARS-CoV-2 and the human internal control (RNase P) in RNA extracted from 14 clinical COVID-19 samples. Detection reactions were incubated at 56°C and the endpoint fluorescent signal was measured with FAM and HEX channels after 1 hour.
- SARS- CoV-2 synthetic SARS-CoV- 2 RNA used at 400 cp/ ⁇ L
- RNase P isolated total human RNA.
- NTC no template control.
- Figure 17D is a heat map showing multiplexed detection of SARS-CoV-2 and the human internal control (RNase P) from 16 clinical oropharyngeal swabs processed with the quick extraction method. Detection reactions were incubated at 56°C and the endpoint fluorescent signal was measured with FAM and HEX channels after 1 hour.
- -Ve SARS-CoV-2 negative samples as determined with RT-qPCR. NTC no template control.
- Figures 18A-18D are bar graphs showing HheCas13a and TccCas13a crRNA screening in two-pot detection reaction.
- NS non-specific crRNA.
- T7-FIP RT-LAMP primers with modified FIP primer carrying T7 promoter sequence.
- T7-BIP RT-LAMP primers with modified BIP primer carrying T7 promoter sequence. The location of the targeted sequence of each crRNA (orange) relative to the RT-LAMP primers (F3, FIP-T7, BIP- T7, B3) is depicted on top of each graph.
- FIP/BIP-T7 primers containing T7 promoter sequence.
- Figure 19 is a heat map showing establishment of one-pot SARS- CoV-2 detection using the thermophilic Cas13 proteins. Trans cleavage activity of HheCas13a and TccCas13a using different crRNAs in one-pot reactions using SARS-CoV-2 genomic standards as input. The assay was performed as described in material and methods. End-point fluorescence signal detection was carried out after 80 min. NTC: No template control.
- T7- FIP modified RT-LAMP FIP primer with T7 promoter sequence.
- Figures 22A-22C illustrate the adaptability of OPTIMA-dx for specific detection of different pathogens.
- Figure 22A is a bar graph showing detection of major HCV genotypes with OPTIMA-dx. In vitro transcribed RNA was used as RNA template in the OPTIMA-dx detection reactions at concentrations of 500 pM. Values are shown as mean ⁇ S.D. and represent endpoint fluorescence at 60 min.
- Figure 22B is a bar graph showing detection of TYLCV DNA virus with OPTIMA-dx. DNA isolated from two different TYLCV infected plants and one healthy (not infected) plant was diluted 1:10 or 1:100 in water and used as template in the OPTIMA-dx detection reactions.
- CRISPR systems have been repurposed for biosensing applications including virus detection.
- Different two-pot modalities have been developed for SARS-CoV-2 detection including Cas13.
- robust one-pot detection assays that involves minimal equipment and handling steps are still elusive.
- the working Examples demonstrate identification and characterization of a thermophilic Cas13a enzyme and show its trans and collateral activities at temperatures between 60-70 °C.
- thermostability features of this enzyme was harnessed to build an assay for sensitive and specific detection of SARS-CoV2.
- the one-pot, isothermal assay couples RT-LAMP, in vitro transcription by thermostable Hi-T7 RNA polymerase, and specific amplicon recognition by thermostable Cas13a effector. This method facilitates handling by eliminating the need for separating amplification and detection steps utilizing only minimal equipment, thereby allowing practical POC application.
- the assay can detect down to 20 copies per microliter of synthetic SARS-CoV-2 genomic RNA. Upon evaluating 8 clinical samples from COVID-19 patients, the assay shows 100% agreement with RT-qPCR.
- RT-LAMP CRISPR/Cas13a assay is a practical, sensitive and robust platform with POC capacity for SARS-CoV2 detection, and for pathogen detection in general.
- the working Examples also describe identification of a miniature Cas13 (mCas13) variant and characterization of its catalytic activity.
- the mCas13 was employed to design, build, and test a SARS-CoV-2 detection module coupling reverse transcription loop-mediated isothermal amplification (RT-LAMP) with the mCas13 system to detect SARS-CoV-2 in synthetic and clinical samples.
- RT-LAMP reverse transcription loop-mediated isothermal amplification
- the mCas13 system exhibited sensitivity and specificity comparable to other CRISPR systems.
- TccCas13a thermophilic organism Thermoclostridium caenicola
- HeCas13a Herbinix hemicellulosilytica
- These Cas13 proteins share several properties such as thermostability and inability to process its own pre-crRNA.
- Use of the proteins in various capacities, including SARS-CoV- 2 diagnostic assays are examplifed. This work expands the repertoire and application of Cas13 enzymes in diagnostics and for potential in vivo applications, including RNA knockdown and editing.
- mCas13, TccCas13a, and HheCas13a systems can be adapted and used in large-scale testing for diverse pathogens, including RNA and DNA viruses, and bacteria.
- “Introduce” in the context of genome modification refers to bringing into contact.
- a vector e.g., encoding an Cas13 effector
- the term encompasses penetration of the contacted composition to the interior of the cell by any suitable means, e.g., via transfection, electroporation, transduction, gene gun, nanoparticle delivery, etc.
- operably linked refers to functional linkage between a regulatory sequence and a heterologous nucleic acid sequence permitting them to function in their intended manner (e.g., resulting in expression of the latter).
- the term encompasses positioning of a regulatory region and a sequence to be transcribed in a nucleic acid so as to influence transcription or translation of such a sequence.
- the translation initiation site of the translational reading frame of the polypeptide is typically positioned between one and about fifty nucleotides downstream of the promoter.
- a promoter can, however, be positioned as much as about 5,000 nucleotides upstream of the translation initiation site or about 2,000 nucleotides upstream of the transcription start site.
- a promoter typically comprises at least a core (basal) promoter.
- the term “expression” encompasses the transcription and/or translation of a particular nucleotide sequence driven by a promoter.
- “Expression vector” or “expression cassette” refers to a vector containing a recombinant polynucleotide having expression control sequences operatively linked to a nucleotide sequence to be expressed.
- An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system.
- Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes), phagemids, BACs, YACs, and viral vectors (e.g., vectors derived from lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.
- viral vectors e.g., vectors derived from lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses
- heterologous refers to elements occurring where they are not normally found.
- a promoter may be linked to a heterologous nucleic acid sequence, e.g., a sequence that is not normally found operably linked to the promoter.
- heterologous means a promoter element that differs from that normally found in the native promoter, either in sequence, species, or number.
- a heterologous control element in a promoter sequence may be a control/ regulatory element of a different promoter added to enhance promoter control, or an additional control element of the same promoter.
- the term “heterologous” thus can also encompass “exogenous” and “non-native” elements.
- polynucleotide generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- polynucleotides as used herein refers to, among others, single-and double-stranded DNA, DNA that is a mixture of single-and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double- stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
- the term “nucleic acid” or “nucleic acid sequence” also encompasses a polynucleotide as defined above.
- a “mutation” refers to a change in a nucleotide (e.g., DNA) or amino acid sequence resulting in an alteration from a given reference sequence.
- the mutation can be a deletion, insertion, duplication, and/or substitution of at least one deoxyribonucleic acid base such as a purine (adenine and/or guanine) and/or a pyrimidine (thymine, uracil and/or cytosine). Mutations may or may not produce discernible changes in the observable characteristics (phenotype) of an subject.
- Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (e.g., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
- a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
- Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
- isolated means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.”
- An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.
- isolated nucleic acid refers to a nucleic acid segment or fragment which has been separated from sequences which flank it in a naturally occurring state, e.g., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment in a genome in which it naturally occurs.
- nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid (e.g., RNA or DNA or proteins, which naturally accompany it in the cell).
- the term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences.
- isolated refers to a cell altered or removed from its natural state. An isolated cell is thus in an environment different from that in which the cell naturally occurs, e.g., separated from its natural milieu such as by concentrating to a concentration at which it is not found in nature.
- isolated cell is meant to include cells that are within samples that are substantially enriched for the cell of interest and/or in which the cell of interest is partially or substantially purified.
- transformed,” “transduced,” and “transfected” encompass the introduction of a nucleic acid or other material into a cell by one of a number of techniques known in the art.
- a “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Examples of vectors include but are not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses.
- the term “vector” includes an autonomously replicating plasmid or a virus.
- the term is also construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like.
- viral vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, and the like.
- the term “percent (%) sequence identity” describes the percentage of nucleotides or amino acids in a candidate sequence that are identical with the nucleotides or amino acids in a reference nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
- Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software.
- Appropriate parameters for measuring alignment including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared can be determined by known methods. “Identity” can be readily calculated by known methods, including, but not limited to, those described in Computational Molecular Biology, Lesk, A. M., Ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.
- the percent identity between two sequences can be determined by using analysis software (i.e., Sequence Analysis Software Package of the Genetics Computer Group, Madison Wis.) that incorporates the Needelman and Wunsch, (J. Mol. Biol., 48: 443-453, 1970) algorithm (e.g., NBLAST, and XBLAST).
- analysis software i.e., Sequence Analysis Software Package of the Genetics Computer Group, Madison Wis.
- Needelman and Wunsch J. Mol. Biol., 48: 443-453, 1970
- algorithm e.g., NBLAST, and XBLAST.
- the default parameters can be used to determine the identity for the polynucleotides or polypeptides of the present disclosure.
- the % sequence identity of a given nucleic acid or amino acid sequence C to, with, or against a given nucleic acid or amino acid sequence D is calculated as follows: 100 times the fraction W/Z, where W is the number of nucleotides or amino acids scored as identical matches by the sequence alignment program in that program’s alignment of C and D, and where Z is the total number of nucleotides or amino acids in D. It will be appreciated that where the length of sequence C is not equal to the length of sequence D, the % sequence identity of C to D will not equal the % sequence identity of D to C.
- each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- any subset or combination of these is also specifically contemplated and disclosed.
- the sub-group of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- contemplated and disclosed as above can also be specifically and independently included or excluded from any group, subgroup, list, set, etc. of such materials.
- These concepts apply to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions.
- steps in methods of making and using the disclosed compositions are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods, including, but not limited to those provided in the exemplary experiments, and that each such combination is specifically contemplated and should be considered disclosed. All methods described herein can be performed in any suitable order unless otherwise indicated or otherwise clearly contradicted by context.
- compositions Compositions of class II, type VI CRISPR/Cas effector proteins or nucleic acids encoding thereof are provided.
- the compositions can include polynucleotides, vectors (e.g., expression vectors), isolated proteins, and/or ribonucleoprotein complexes related to class II, type VI CRISPR/Cas effectors.
- CRISPR CRISPR-associated
- CRISPR–Cas CRISPR-associated systems
- the second component of CRISPR–Cas systems are Cas proteins., which are encoded by cas genes, usually located in the proximity of a CRISPR array. See Burmistrz, M., et al., Int J Mol Sci., 21(3):1122 (2020).
- the mechanism of CRISPR–Cas systems includes three phases: adaptation, maturation, and interference.
- adaptation phase new spacers are incorporated into the CRISPR array into its leader end.
- the CRISPR array is transcribed.
- the resulting transcript called pre-CRISPR RNA (pre-crRNA) is further processed into a set of CRISPR RNA (crRNA) molecules, each containing a single spacer flanked by fragments of a repeat sequence.
- crRNAs are incorporated into ribonucleoprotein (RNP) complexes together with Cas proteins.
- RNP complexes scan nucleic acids searching for a sequence complementary to that encoded by crRNA.
- CRISPR systems are classified based on the structure of CRISPR-associated (Cas) genes that are typically adjacent to the CRISPR arrays. Generally, there are two classes of CRISPR systems, each containing multiple CRISPR types. Class 1 contains type I and type III CRISPR systems that are commonly found in Archaea. Class 2 contains type II, IV, V, and VI CRISPR systems (Adli, M., Nat Commun., 9:1911 (2018)).
- VI-A that uses Cas13a variant, alternatively known as C2c2
- VI-B that uses Cas13b/C2c6
- VI-C that uses Cas13c/C2c7
- VI-D that uses Cas13d
- the Cas13 of these subtypes differ in size and sequence, they all share a common feature, which is the presence of two HEPN domains. These domains are responsible for RNA- targeted nucleolytic activity. HEPN domains are usually located close to different terminal ends of the Cas13 protein.
- processing of pre-crRNA into crRNA is performed by Cas13 itself in a metal-independent manner (with the exception of type VI- D) without the help of other host factors.
- subtypes VI-A, VI-C, and VI-D crRNAs contain a repeat-derived handle on their 5′ end.
- subtype VI-B generates crRNAs with handle on the 3′ end. Secondary processing is presumably performed by other host nucleases. crRNA maturation is not necessary for type VI activity, and even unprocessed pre- crRNA is sufficient for recognition of targeted RNA.
- the complex of Cas13 and cRNA presents no nucleolytic activity until it binds to targeted ssRNA.
- CRISPR/Cas composition refers to the elements of a CRISPR system needed to carry out CRISPR/Cas-mediated activity.
- CRISPR/Cas-mediated compositions typically include one or more nucleic acids encoding a crRNA, a tracrRNA (or chimeric thereof also referred to a guide RNA or single guide RNA) and a Cas enzyme, preferably Cas13.
- the methods of delivery disclosed herein are suitable for use with numerous variations on the CRISPR/Cas system.
- a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system).
- target sequence refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex.
- a target sequence can be any polynucleotide, such as DNA or RNA polynucleotides.
- a target sequence is located in the nucleus or cytoplasm of a cell. All type VI systems require a so called Protospacer Flanking Sequence (PFS) located in the direct vicinity of a protospacer sequence. This sequence varies between different subtypes.
- PFS Protospacer Flanking Sequence
- LshCas13a uses a non-G PFS located at 3′ end
- BzCas13b requires the double-sided PFS of non-C upstream of the target site and NAN or NNA downstream of the target site.
- the tracrRNA duplex directs Cas to the target consisting of the protospacer and the requisite PSF via heteroduplex formation between the spacer region of the crRNA and the protospacer.
- formation of a CRISPR complex results in cleavage of the RNA strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence.
- nucleic acids can be in sense or antisense orientation, or can be complementary to a reference sequence encoding a Cas13 or variant thereof such as those discussed below.
- Nucleic acids can be DNA, RNA, or nucleic acid analogs.
- Nucleic acid analogs can be modified at the base moiety, sugar moiety, or phosphate backbone. Such modification can improve, for example, stability, hybridization, or solubility of the nucleic acid.
- Modifications at the base moiety can include deoxyuridine for deoxythymidine, and 5-methyl-2’- deoxycytidine or 5-bromo-2’-deoxycytidine for deoxycytidine.
- Modifications of the sugar moiety can include modification of the 2’ hydroxyl of the ribose sugar to form 2’-O-methyl or 2’-O-allyl sugars.
- the deoxyribose phosphate backbone can be modified to produce morpholino nucleic acids, in which each base moiety is linked to a six membered, morpholino ring, or peptide nucleic acids, in which the deoxyphosphate backbone is replaced by a pseudopeptide backbone and the four bases are retained.
- polynucleotides containing a nucleotide sequence encoding a class II, type VI CRISPR/Cas effector protein (Cas13) and a heterologous sequence are disclosed.
- the CRISPR/Cas effector is an RNA editing enzyme (e.g., RNA endonuclease) with RNA (e.g., ssRNA) cleavage activity.
- the Cas13 enzyme is a Cas13a protein derived from thermophilic bacteria, preferably from Thermoclostridium caenicola (TccCas13a) or Herbinix hemicellulosilytica (HheCas13a).
- HheCas13a DNA sequences for HheCas13a are known in the art. See e.g., Addgene plasmid No.: 91871 and East-Seletsky, et al., Mol Cell, 2017, which are hereby incorporated by reference in their entirety.
- An exemplary DNA sequence encoding HheCas13a is: ATGAAGTTGACGCGTCGCCGCATCAGTGGCAATTCAGTCGACCAGAAGATT ACAGCTGCGTTTTATCGTGATATGTCGCAAGGGTTATTATATTATGATTCG GAGGACAATGACTGTACGGACAAGGTCATCGAAAGTATGGATTTCGAACGC TCTTGGCGTGGACGCATTCTGAAGAACGGCGAGGATGATAAGAATCCGTTT TACATGTTCGTTAAAGGTTTAGTTCCAACGATAAGATCGTGTGCGAA CCTATCGACGTCGACTCAGACCCTGATAACTTAGATATCTTGATTAACAAA AATCTGACGGGGTTCGGACGCAACTTGAAAGCACCTGACAGTAACGATACC TTAGAAAATCTGACGGGGTTCGGACGCAACTTGAAAGCACCTGACAGTAACGATACC TTAGAAAATCTGACGGGGTTCGGACGCAACTTGAAAGCACCTGACAGTAACGATACC TTAGAAAATCTG
- TccCas13a is: ATGAAGATCACGAAAAGGAAATGGGGAGAGCATCATCCGCCGCTTTACTTC TACCGGGATGAGGACTCCGGCAGGCTCCTGGCACAGAACGACAGAAAGCAG GATTATACCGATACCCTGTTTAATGATATTGCGCAGGATACATTTGAAAGA TCGCTGAGAAACCGGCTTTTGAAAACACCCGAAAAGGGAGACAAAAGATTC TACAGCAACGAGATCGTCAAGCTGGTGGAGAAACTGTGCCAGGGTGCGGAT GTGGCGGAGATCATGAAAAGCATGGAGAGGAACGAAAAGCTGCGCCCCAAG AATGAAAAAGATTAAAAATCTGAAAAAGCAATTGGACGGTACCCTTTCC GAATACGGTAAAAGGTATACCGCCCCAGAAGGCCATGACCCTCAACGAT GCCTTGTTTTTTACCTGGTAGAAGGAAACCCTTTAAAGCAGGCCATGGCCAAA GCTGAACTGGGCAAAATCCGG
- the Cas13 effector is a Cas13 protein derived from a bacterium in the Proteobacteria phylum.
- An exemplary Proteobacteria-derived Cas13 is mCas13 encoded by the following DNA sequence: ATGGGTATTGATTATTCGCTTACAAGTGACTGTTATCGAGGCATCAACAAG TCTTGTTTTGCAGTTGCTTTGAATATTGCATATGATAACTGTGATCATAAA GGATGTAGGACTCTTCTGAGTGAGGTGCTGCGCAGCAAGGGAGGGATTTCT GATGAGCAAATAAAATCACAAGTAGTGGATGGAATTCAGAAGCGACTTAAA GACATTCGCAATTATTTCTCGCATTATTACCACGCAGAAGACTGTCTGCGG TTTGGAGACCAAGATGCCGTCAAGGTTTTTCTGGAAGAAATATACAAGAAC GCGGAATCAAAGACTGTCGGAGCGACAAAAGAAAGCGACTATAAAGGCGTT GTGCCGCCATTTGAATTGCATAACGG
- the sequence encodes the Cas13 effector protein of SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68. In some embodiments, the sequence encodes the Cas13 effector protein with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to Cas13 encoded by SEQ ID NO:63, SEQ ID NO:65, or SEQ ID NO:67. In some embodiments, the sequence encoding the Cas13 effector protein is or includes SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67.
- the sequence encoding the Cas13 effector protein is or includes a sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67.
- the sequence encoding the Cas13 effector protein is codon optimized for expression in a prokaryotic or eukaryotic cell, such as a bacterial, yeast, or mammalian cell.
- the eukaryotic cells can be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, cat, dog, horse, pig, or non-human primate.
- codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence.
- Various species exhibit particular bias for certain codons of a particular amino acid.
- Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules.
- mRNA messenger RNA
- tRNA transfer RNA
- the predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the “Codon Usage Database”, and these tables can be adapted in a number of ways. See Nakamura, Y., et al., Nucl.
- the heterologous sequence includes one or more expression control sequences.
- the heterologous sequence includes a promoter, transcription terminator, multiple cloning site, drug resistance marker(s), one or more protease recognition sites, one or more epitope tags, or a combination thereof.
- the heterologous sequence such as an expression control sequence
- the polynucleotide further includes a sequence encoding one or more crRNAs or guide RNA (gRNA) or single guide (sgRNA).
- the crRNAs are capable of complexing with the Cas13 effector protein and hybridizing to one or more target RNA sequences.
- the polynucleotide is or is contained in a vector, such as an expression vector. Nucleic acids, such as those described above, can be inserted into vectors for expression in cells.
- a “vector” is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment.
- Vectors can be expression vectors.
- An “expression vector” is a vector that includes one or more expression control sequences
- an “expression control sequence” is a DNA sequence that controls and regulates the transcription and/or translation of another DNA sequence.
- Nucleic acids in vectors can be operably linked to one or more expression control sequences.
- “operably linked” means incorporated into a genetic construct so that expression control sequences effectively control expression of a coding sequence of interest.
- expression control sequences include promoters, enhancers, and transcription terminating regions.
- a promoter is an expression control sequence composed of a region of a DNA molecule, typically within 100 nucleotides upstream of the point at which transcription starts (generally near the initiation site for RNA polymerase II). To bring a coding sequence under the control of a promoter, it is necessary to position the translation initiation site of the translational reading frame of the polypeptide between one and about fifty nucleotides downstream of the promoter.
- Enhancers provide expression specificity in terms of time, location, and level. Unlike promoters, enhancers can function when located at various distances from the transcription site. An enhancer also can be located downstream from the transcription initiation site.
- a coding sequence is “operably linked” and “under the control” of expression control sequences in a cell when RNA polymerase is able to transcribe the coding sequence into mRNA, which then can be translated into the protein encoded by the coding sequence.
- Suitable expression vectors include, without limitation, plasmids and viral vectors derived from, for example, bacteriophage, baculoviruses, tobacco mosaic virus, herpes viruses, cytomegalo virus, retroviruses, vaccinia viruses, adenoviruses, and adeno-associated viruses.
- suitable vectors include viral vectors (e.g., retroviral, lentiviral, adenoviral, adeno-associated or herpes simplex viral vectors) or plasmids.
- viral vectors e.g., retroviral, lentiviral, adenoviral, adeno-associated or herpes simplex viral vectors
- An expression vector can include a tag sequence. Tag sequences, are typically expressed as a fusion with the encoded polypeptide. Such tags can be inserted anywhere within the polypeptide including at either the carboxyl or amino terminus.
- useful tags include, but are not limited to, green fluorescent protein (GFP), glutathione S-transferase (GST), polyhistidine, c-myc, hemagglutinin, FlagTM tag (Kodak, New Haven, CT), maltose E binding protein and protein A.
- GFP green fluorescent protein
- GST glutathione S-transferase
- polyhistidine polyhistidine
- c-myc hemagglutinin
- FlagTM tag Kodak, New Haven, CT
- maltose E binding protein and protein A e E binding protein and protein A.
- one or more vectors driving expression of one or more elements of a CRISPR/Cas13 system are introduced into a target cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target RNA sequences.
- a Cas13 protein and one or more guide sequences could each be operably linked to separate regulatory elements on separate vectors.
- two or more of the elements expressed from the same or different regulatory elements may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR/Cas13 system not included in the first vector.
- CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to (“upstream” of) or 3' with respect to (“downstream” of) a second element.
- the coding sequence of one element can be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction.
- a single promoter drives expression of a transcript encoding a Cas13 protein and one or more of the crRNA sequences.
- one or more of the elements of CRISPR/Cas13 system are under the control of an inducible promoter, which can include inducible Cas13.
- a vector includes one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a “cloning site”).
- one or more insertion sites e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
- a vector includes an insertion site upstream of a crRNA sequence, and optionally downstream of a regulatory element operably linked to the crRNA sequence, such that following insertion of a Cas13 sequence into the insertion site and upon expression the crRNA sequence directs sequence-specific binding of a Cas13 RNP complex to a target RNA sequence in a cell.
- a vector includes two or more insertion sites.
- the two or more crRNA sequences can include two or more copies of a single crRNA sequence, two or more different crRNA sequences, or combinations of these.
- a single expression construct may be used to target Cas13 activity to multiple different, corresponding target RNA sequences within a cell.
- a single vector can include about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 crRNA sequences.
- about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, such crRNA-sequence-containing vectors may be provided, and optionally delivered to a cell.
- the relatively small size of mCas13 allows for easier packaging into commonly used delivery vectors such as adeno- associated viruses (AAV).
- AAV adeno- associated viruses
- the AAV vector can provide one or more elements of the gene editing compositions (e.g., crRNA expression cassette, CAR expression cassette, homology arms).
- AAV is a non-pathogenic, single-stranded DNA virus that has been actively employed over the years for delivering therapeutic genes in both in vitro and in vivo systems (Choi, et al., Curr. Gene Ther., 5:299-310, (2005)).
- AAV belongs to the parvovirus family and is dependent on co-infection with other viruses, mainly adenoviruses, in order to replicate. Initially distinguished serologically, molecular cloning of AAV genes has identified hundreds of unique AAV strains in numerous species.
- Each end of the single-stranded DNA genome contains an inverted terminal repeat (ITR), which is the only cis-acting element required for genome replication and packaging.
- ITR inverted terminal repeat
- the single-stranded AAV genome contains three genes, Rep (Replication), Cap (Capsid), and aap (Assembly). These three genes give rise to at least nine gene products through the use of three promoters, alternative translation start sites, and differential splicing. These coding sequences are flanked by the ITRs.
- the Rep gene encodes four proteins (Rep78, Rep68, Rep52, and Rep40), while Cap expression gives rise to the viral capsid proteins (VP; VP1/VP2/VP3), which form the outer capsid shell that protects the viral genome, as well as being actively involved in cell binding and internalization. It is estimated that the viral coat is comprised of 60 proteins arranged into an icosahedral structure with the capsid proteins in a molar ratio of 1:1:10 (VP1:VP2:VP3).
- Suitable AAV vectors can be a naturally occurring serotype of AAV including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, artificial variants such as AAV.rhlO, AAV.rh32/33, AAV.rh43, AAV.rh64Rl, rAAV2-retro, AAV-DJ, AAV-PHP.B, AAV-PHP.S, AAV-PHP.eB, or other natural or engineered versions of AAV. Twelve natural serotypes of AAV have thus far been identified, with the best characterized and most commonly used being AAV2.
- AAV serotypes differ in their tropism, or the types of cells they infect, making AAV a very useful system for preferentially transducing specific cell types.
- AAV serotypes 1, 2, 5 or a hybrid capsid AAV1, AAV2, AAV5 or any combination thereof can be used for targeting brain or neuronal cells; AAV4 can be selected for targeting cardiac cells.
- AAV8 is useful for delivery to the liver cells.
- researchers have further refined the tropism of AAV through pseudotyping, or the mixing of a capsid and genome from different viral serotypes. These serotypes are denoted using a slash, so that AAV2/5 indicates a virus containing the genome of serotype 2 packaged in the capsid from serotype 5.
- An exemplary sequence of an expression vector, a plasmid in particular, containing a nucleic acid sequence encoding TccCas13a is: tcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagacc ccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaa tctgcttgcaaacaaaaaaccaccgctaccagcggtggtttgttgc cggatcaagagctaccaactcttttccgaaggtaactggct
- An exemplary sequence of an expression vector, a plasmid in particular, containing a nucleic acid sequence encoding mCas13a is: tttcctgtttggtcactgatgcctccgtgtaagggggatttctgttcatgg gggtaatgataccgatgaaacgagagaggatgctcacgatacgggttactg atgatgaacatgcccggttactggaacgttgtgagggtaacaactggcgg tatggatgcggcgggaccagagaaaaatcactcagggtcaatgccagcgct tcgttaatacagatgtaggtgttccacagggtagccagcagcatcctgcga tgcagatccggaacataatggtgcagggttttccagggtagccagcagcatcctgc
- mCas13 coding sequence is in capital letters, preceded by vector sequence and sequence encoding 6x His affinity tag, Thrombin site, Strep-tag II, SUMO, and followed by additional vector sequence in lowercase letters.
- Suitable expression vectors for expressing the disclosed Cas13 effectors include vectors having a nucleotide sequence with at least 60% sequence identity to SEQ ID NO:69 or 70. While the specifics can be varied in different engineered CRISPR systems, the overall methodology is similar. A practitioner interested in using the CRISPR/Cas13 technology to target an RNA sequence (identified using one of the many available online tools) can insert a short DNA fragment containing the target sequence into a guide RNA expression plasmid.
- the expression plasmid contains the target sequence (or spacer), one or more direct repeat sequences, as well as a suitable promoter and necessary elements for proper processing in a cell of interest.
- Such vectors are commercially available (see, for example, Addgene). Many of the systems rely on custom, complementary oligos that are annealed to form a double stranded DNA and then cloned into the crRNA expression plasmid. Co-expression of the crRNA(s) and the appropriate Cas13 enzyme from the same or separate plasmids in transfected cells can result in a target RNA cleavage (depending of the activity of the Cas enzyme) at the desired target site.
- B. Cells Vectors containing nucleic acids to be expressed can be transferred into host cells.
- host cell is intended to include prokaryotic and eukaryotic cells into which a recombinant expression vector can be introduced.
- transformed encompass the introduction of a nucleic acid molecule (e.g., a vector) into a cell by one of a number of techniques. Although not limited to a particular technique, a number of these techniques are well established within the art.
- Prokaryotic cells can be transformed with nucleic acids by, for example, electroporation or calcium chloride mediated transformation.
- Nucleic acids can be transfected into mammalian cells by techniques including, for example, calcium phosphate co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, or microinjection.
- Host cells e.g., a prokaryotic cell or a eukaryotic cell such as a CHO cell
- Cells harboring the polynucleotides, vectors, proteins, RNPs, and/or other compositions disclosed herein are also provided.
- prokaryotic or eukaryotic cells containing the polynucleotide and/or vector are disclosed.
- the cell can be a mammalian cell.
- the mammalian cell can be human or non-human mammal, e.g., primate, bovine, ovine, porcine, canine, rodent, monkey, rat, or mouse cell.
- the cell can be a non-mammalian eukaryotic cell such as poultry bird (e.g., chicken), vertebrate fish (e.g., salmon) or shellfish (e.g., oyster, claim, lobster, shrimp) cell.
- the cell can also be a plant cell.
- the cell is a human cell including, but not limited to, skin cells, lung cells, heart cells, kidney cells, pancreatic cells, muscle cells, neuronal cells, human embryonic stem cells, blood cells (e.g., white blood cells), and pluripotent stem cells.
- the cell can be T cells (e.g., CD8+ T cells such as effector T cells, memory T cells, central memory T cells, and effector memory T cells; or CD4+ T cells such as Th1 cells, Th2 cells, Th3 cells, Th9 cells, Th17 cells, Tfh cells, and Treg cells; or gamma- delta T cells / gdT cells), hematopoietic stem cells (HSC), macrophages, natural killer cells (NK), B cells, dendritic cells (DC), or other immune cells.
- CD8+ T cells such as effector T cells, memory T cells, central memory T cells, and effector memory T cells
- CD4+ T cells such as Th1 cells, Th2 cells, Th3 cells, Th9 cells, Th17 cells, Tfh cells, and Treg cells
- gamma- delta T cells / gdT cells hematopoietic stem cells (HSC), macrophages, natural killer cells (NK), B cells, dendritic cells (DC),
- the cell can be from established cell lines or they can be primary cells, where “primary cells,” refers to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages or splittings of the culture.
- the Cas13 compositions can be introduced to the cell through a variety of techniques, including viral or non-viral approaches.
- the Cas13 and/or crRNA can be introduced via a viral vector (e.g., a retrovirus such as a lentivirus, adenovirus, poxvirus, Epstein-Barr virus, or adeno-associated virus (AAV)).
- a viral vector e.g., a retrovirus such as a lentivirus, adenovirus, poxvirus, Epstein-Barr virus, or adeno-associated virus (AAV)
- Non-viral approaches such as physical and/or chemical methods can also be used, including, but not limited to cationic liposomes and polymers, DNA nanoclew, gene gun, microinjection, transfection, electroporation, nucleofection, particle bombardment, ultrasound utilization, magnetofection, conjugation to cell penetrating peptides, and/or nanoparticle mediated delivery.
- cationic liposomes and polymers DNA nanoclew, gene gun, microinjection, transfection, electroporation, nucleofection, particle bombardment, ultrasound utilization, magnetofection, conjugation to cell penetrating peptides, and/or nanoparticle mediated delivery.
- Such methods are described for example, in Nayerossadat N., et al., Adv. Biomed. Res., 1:27 (2012) and Lino CA, et al., Drug Deliv., 25(1):1234-1257 (2016).
- the cas13 protein is produced by expressing a disclosed polynucleotide or expression vector in a desired cell, and optionally purifying the protein from the cell.
- the Cas13 proteins are thermostable enzymes. The working examples demonstrate that HheCas13a exhibits robust activity at temperatures up to 60 oC while TccCas13a maintained a robust activity at temperatures as high as ⁇ 70 oC.
- the Cas13 enzyme exhibits ssRNA cleavage activity at a temperature of about 37-70 o C. In some embodiments, the Cas13 enzyme exhibits ssRNA cleavage activity at a temperature of about 47-60 o C. In some embodiments, the Cas13 enzyme exhibits ssRNA cleavage activity at a temperature of about 37-42 o C. In some embodiments, the Cas13 enzyme exhibits ssRNA cleavage activity at a temperature of about 60 oC. In preferred embodiments, the Cas13 protein contains one or more Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) domains.
- HEPN Higher Eukaryotes and Prokaryotes Nucleotide-binding
- the Cas13 protein includes two HEPN domains.
- An exemplary HEPN domain is a RxxxxH (SEQ ID NO:192) motif sequence, wherein X represents any amino acid.
- a HEPN domain can include at least one RxxxxH (SEQ ID NO:192) motif having the sequence of R[N/H/K]X1X2X3H.
- an HEPN domain includes a RxxxxH (SEQ ID NO:192) motif having the sequence of R[N/H]X 1 X 2 X 3 H (SEQ ID NO:193).
- a HEPN domain has the sequence of R[N/K]X 1 X 2 X 3 H (SEQ ID NO:194).
- X 1 is R, S, D, E, Q, N, G, Y, or H.
- X 2 is I, S, T, V, or L.
- X 3 is L, F, N, Y, V, I, S, D, E, or A.
- the Cas13 protein is a Cas13a protein derived from thermophilic bacteria, preferably from Thermoclostridium caenicola (TccCas13a) or Herbinix hemicellulosilytica (HheCas13a).
- An exemplary amino acid sequence for HheCas13a is: MKLTRRRISGNSVDQKITAAFYRDMSQGLLYYDSEDNDCTDKVIESMDFER SWRGRILKNGEDDKNPFYMFVKGLVGSNDKIVCEPIDVDSDPDNLDILINK NLTGFGRNLKAPDSNDTLENLIRKIQAGIPEEEVLPELKKIKEMIQKDIVN RKEQLLKSIKNNRIPFSLEGSKLVPSTKKMKWLFKLIDVPNKTFNEKMLEK YWEIYDYDKLKANITNRLDKTDKKARSISRAVSEELREYHKNLRTNYNRFV SGDRPAAGLDNGGSAKYNPDKEEFLLFLKEVEQYFKKYFPVKSKHSNKSKD KSLVDKYKNYCSYKVVKKEVNRSIINQLVAGLIQQGKLLYYFYYNDTWQED FLNSYGLSYIQVEEAFKKSVMTSLSWGINRLTSFFIDDSNTV
- TccCas13a An exemplary amino acid sequence for TccCas13a is: MKITKRKWGEHHPPLYFYRDEDSGRLLAQNDRKQDYTDTLFNDIAQDTFER SLRNRLLKTPEKGDKRFYSNEIVKLVEKLCQGADVAEIMKSMERNEKLRPK NEKEIKNLKKQLDGTLSEYGKRYTAPEGAMTLNDALFYLVEGNPLKQAMAK AELGKIREALIKEKENRINRVRYSIKNNKIPLRIQEDGGITPNNDRAAWLL GLMKPADPAKGITDCYPLLGELEEVFDFDKLSKTLHEKISRCQGRPRSIAM AVDEALKQYLRELWEKSPSRQQDLKYYFQAVQEYFKDNFPIRTKRMGARLR QELLKDKTSLSRLLEPKHMANAVRRRLINQSTQMHILYGKLYAYCCGEDGR LLVNSETLQRIQVHEAVKKQAMTAVLWSISRL
- the Cas13 protein is a Cas13 protein originated, isolated or derived from a bacterium in the Proteobacteria phylum.
- An exemplary Proteobacteria-derived Cas13 is mCas13 having the following amino acid sequence: MGIDYSLTSDCYRGINKSCFAVALNIAYDNCDHKGCRTLLSEVLRSKGGIS DEQIKSQVVDGIQKRLKDIRNYFSHYYHAEDCLRFGDQDAVKVFLEEIYKN AESKTVGATKESDYKGVVPPLFELHNGTYMITAAGVIFLASFFCHRSNVYR MLGAVKGFKHTGKEQLSDGQKRDYGFTRRLLAYYALRDSYSVGAEDKTRCF REILSYLSRVPQLAVDWLNEQQLLTPEEKEAFLNQPAEDEGGDISDSSSSD KNKKSKEKRRSLRRDEKFILFAIQFIEGWAAEQGLDVTFARYQKTVEKAEN KNQDGK
- the Cas13 protein includes the amino acid sequence of SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68.
- the Cas13 protein includes an amino acid sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68 or Uniprot accession numbers disclosed herein, and including nucleic acid sequences encoding amino acid sequences thereof. ii.
- Cas13 variants and modifications are Cas13 effector protein variants including one or more mutations (e.g., conservative or non- conservative mutations) relative to any of the Cas effector proteins disclosed herein.
- other Cas13 variants can be evolved from those disclosed herein, for example, by targeted mutation of one or more amino acid residues in specific regions of the enzyme.
- Such mutation(s) may alter substrate binding, alter conformation of bound substrate, alter substrate accessibility to the active site, alter tolerance to non- optimal presentation of a target sequence to the active site, and/or alter target sequence specificity (recognition).
- a suitable Cas13 effector protein has an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NO:64, 66 or 68.
- a disclosed Cas13 protein e.g., encoded by a polynucleotide or vector, contained in an RNP, or expressed in a cell
- the Cas13 is engineered and can include one or more mutations that reduce or eliminate a nuclease activity. Mutations can also be made at neighboring residues, e.g., at amino acids near those that participate in the nuclease activity. In some embodiments, one HEPN domain is inactivated. In other embodiments, a second HEPN domain is inactivated.
- the mutated Cas13 enzyme can have abolished or reduced ability to cleave a target polynucleotide containing a target sequence.
- a Cas13 enzyme is considered to substantially lack all cleavage activity when the RNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%>, 1%>, 0.1 %>, 0.01%, or lower with respect to its non-mutated form.
- RNA cleavage is mediated by catalytic residues in the two conserved HEPN domains of Cas13. Therefore, catalytically dead or inactive Cas13 mutants can be generated by mutating one or more catalytic residues within the HEPN domains (e.g., via Alanine substitution). Such mutations can render the Cas13 as a catalytically inactive RNA-binding protein.
- the one or more mutated residues are one or more residues in the disclosed Cas13 proteins that correspond to R597, H602, R1278 and H1283 of Leptotrichia shahii Cas 13 (LshCasl3), such as mutations R597A, H602A, R1278A and H1283A.
- the Cas13 proteins may be modified in various ways. In some embodiments, the modification(s) may render the protein more stable (e.g., resistant to degradation in vivo) or more capable of penetrating into cells or subcellular compartments, or other desirable characteristic as will be appreciated by one skilled in the art.
- modifications include, without limitation, chemical modification, N terminus modification, C terminus modification, peptide bond modification, backbone modifications, residue modification, D-amino acids, or non-natural amino acids or others.
- one or more modifications may be used simultaneously.
- the modifications may or may not cause an altered functionality.
- modifications which do not result in an altered functionality include for instance codon optimization for expression into a particular host, or providing the Cas13 with a particular marker or epitope tag (e.g. for visualization and/or isolation or purification).
- a disclosed Cas13 protein can be fused to or operably linked to domains which include but are not limited to a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light inducible/controllable domain, a chemically inducible/controllable domain, a detectable marker, or a deaminase domain.
- domains include but are not limited to a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light inducible/controllable domain, a chemically inducible/controllable domain, a detectable marker, or a deaminase domain.
- Exemplary detectable markers include fluorescent proteins, such as, GFP, eGFP, RFP, YFP, BFP, CFP, mNeonGreen, mCherry, mOrange, mRaspberry, mPlum, mKO, mRFP, mRFPruby, mRuby, tagRFP, mKate2, and DsRed.
- the Cas13 is covalently linked to the one or more domains.
- the Cas13 is covalently linked to the one or more domains via one or more linkers (e.g., peptide linkers).
- the Cas13 protein is a fusion protein including the Cas13 effector and one or more domains, such as those described herein.
- exemplary deaminase domains include deaminase domains of the RNA-dependent Adenosine Deaminases (ADAR) such as ADAR1, ADAR2, and ADAR3, e.g., human ADAR1, ADAR2, and ADAR3.
- ADAR RNA-dependent Adenosine Deaminases
- the ADARs catalyze the hydrolytic deamination of adenosine to inosine in double- stranded RNA (dsRNA) in a process generally referred to as A-to-I RNA editing.
- the Cas13 protein includes one or more nuclear localization sequences (NLSs).
- NLSs nuclear localization sequences
- an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N-or C-terminus.
- the one or more NLSs are of sufficient strength to drive accumulation of the Cas13 enzyme in a detectable amount in the nucleus of a eukaryotic cell.
- strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors.
- the Cas13 protein can be modified with one or more (e.g., two or more, three or more, or four or more) mitochondrial localization sequences (MLSs).
- Any convenient mitochondrial localization sequence can be used.
- mitochondrial localization sequences include a mitochondrial localization sequence of SDHB, mono/di/triphenylphosphonium or other phosphoniums, VAMP 1A, VAMP 1B, the 67 N-terminal amino acids of DGAT2, and the 20 N-terminal amino acids of Bax.
- the MLS(s) can be placed at the N- or C-termini of the Cas13 protein. iii.
- the Cas13 protein is complexed with an RNA including or consisting of a crRNA sequence (e.g., a gRNA, sgRNA, etc.), thereby forming a ribonucleoprotein (RNP) complex.
- the crRNA may be capable of hybridizing to a target RNA sequence, such as an mRNA, lincRNA, or viral RNA (e.g., SARS-Cov-2 N or E gene transcript).
- the crRNA can include a spacer sequence that is capable of hybridizing to the target RNA sequence and a direct repeat sequence.
- the guide RNA or crRNA is or includes a direct repeat sequence linked to a guide sequence or spacer sequence.
- the guide RNA or mature crRNA includes about 19 nucleotides of partial direct repeat followed by 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more nucleotides of guide or spacer sequence, such as 18-30, 20-25, 25-30, 21-25, 22-25, 23-25, or 25-28 nucleotides of guide or spacer sequence.
- the crRNA includes a spacer of about 20-30 nucleotides.
- the crRNA includes a spacer of about 24-28 nucleotides.
- the crRNA contains a stem loop or other secondary structure.
- the crRNA contains a stem loop or other secondary structure in the direct repeat sequence, wherein the stem loop or secondary structure is important for cleavage activity.
- Exemplary crRNAs that can be included in the Cas13 RNP complex are crRNAs encoded by the nucleic acid sequence of SEQ ID NOs:20-37 and 41-61, sequences having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto, nucleic acid sequences having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleic acid substitution(s), addition(s), deletion(s), or a combination thereof relative thereto, or the reverse complement of any of the foregoing.
- Cas13 polypeptides and fusions proteins thereof can be obtained by, for example, chemical synthesis or by recombinant production in a host cell.
- a nucleic acid containing a nucleotide sequence encoding the polypeptide can be used to transform, transduce, or transfect a bacterial or eukaryotic host cell (e.g., an insect, yeast, or mammalian cell).
- nucleic acid constructs include a regulatory sequence operably linked to a nucleotide sequence encoding a Cas13 polypeptide.
- Regulatory sequences typically do not encode a gene product, but instead affect the expression of the nucleic acid sequences to which they are operably linked.
- Useful prokaryotic and eukaryotic systems for expressing and producing polypeptides are well known in the art and include, for example, Escherichia coli strains such as BL-21, and cultured mammalian cells such as CHO cells.
- Escherichia coli strains such as BL-21
- mammalian cells such as CHO cells.
- viral-based expression systems can be utilized to express antigenic polypeptides or fusions proteins.
- Viral based expression systems are well known in the art and include, but are not limited to, baculoviral, SV40, retroviral, or vaccinia based viral vectors.
- Mammalian cell lines that stably express Cas13 polypeptides or fusions proteins can be produced using expression vectors with appropriate control elements and a selectable marker.
- the eukaryotic expression vectors pCR3.1 (Invitrogen Life Technologies) and p91023(B) are suitable for expression of variant costimulatory polypeptides in, for example, Chinese hamster ovary (CHO) cells, COS-1 cells, human embryonic kidney 293 cells, NIH3T3 cells, BHK21 cells, MDCK cells, and human vascular endothelial cells (HUVEC).
- transfected cells can be cultured such that the polypeptide of interest is expressed, and the polypeptide can be recovered from, for example, the cell culture supernatant or from lysed cells.
- a antigenic polypeptides and fusion proteins can be produced by (a) ligating amplified sequences into a mammalian expression vector such as pcDNA3 (Invitrogen Life Technologies), and (b) transcribing and translating in vitro using wheat germ extract or rabbit reticulocyte lysate.
- Cas13 polypeptides and fusion proteins can be isolated using, for example, chromatographic methods such as DEAE ion exchange, gel filtration, and hydroxylapatite chromatography.
- Cas13 proteins in a cell culture supernatant or a cytoplasmic extract can be isolated using a protein G column.
- Cas13 proteins are “engineered” to contain an amino acid sequence that allows the polypeptides to be captured onto an affinity matrix.
- a tag such as c-myc, hemagglutinin, polyhistidine, or FlagTM (Kodak) can be used to aid polypeptide purification.
- tags are typically inserted at either the carboxyl or amino terminus.
- Other fusions that can be useful include enzymes that aid in the detection of the polypeptide, such as alkaline phosphatase.
- Immunoaffinity chromatography also can be used to purify antigenic polypeptides and fusions proteins.
- Isolated nucleic acid molecules encoding Cas13 polypeptides and fusion proteins can be produced by standard techniques, including, without limitation, common molecular cloning and chemical nucleic acid synthesis techniques. For example, polymerase chain reaction (PCR) techniques can be used to obtain an isolated nucleic acid encoding an Cas13 polypeptide. PCR is a technique in which target nucleic acids are enzymatically amplified. Typically, sequence information from the ends of the region of interest or beyond can be employed to design oligonucleotide primers that are identical in sequence to opposite strands of the template to be amplified.
- PCR polymerase chain reaction
- PCR can be used to amplify specific sequences from DNA as well as RNA, including sequences from total genomic DNA or total cellular RNA.
- Primers typically are 14 to 40 nucleotides in length, but can range from 10 nucleotides to hundreds of nucleotides in length.
- General PCR techniques are described, for example in PCR Primer: A Laboratory Manual, ed. by Dieffenbach and Dveksler, Cold Spring Harbor Laboratory Press, 1995.
- reverse transcriptase can be used to synthesize a complementary DNA (cDNA) strand.
- Ligase chain reaction, strand displacement amplification, self-sustained sequence replication or nucleic acid sequence-based amplification also can be used to obtain isolated nucleic acids.
- Isolated nucleic acids can be chemically synthesized, either as a single nucleic acid molecule or as a series of oligonucleotides (e.g., using phosphoramidite technology for automated DNA synthesis in the 3’ to 5’ direction).
- one or more pairs of long oligonucleotides can be synthesized that contain the desired sequence, with each pair containing a short segment of complementarity (e.g., about 15 nucleotides) such that a duplex is formed when the oligonucleotide pair is annealed.
- DNA polymerase can be used to extend the oligonucleotides, resulting in a single, double-stranded nucleic acid molecule per oligonucleotide pair, which then can be ligated into a vector.
- compositions and reagents including Cas13 proteins, Cas13 fusion proteins and other engineered variants, crRNAs, etc.
- methods of perturbing e.g., reducing or increasing
- RNA editing deaminating a target nucleic acid
- a method of modifying a target locus of interest in particular in eukaryotic cells, tissues, organs, or organisms, more in particular in mammalian cells, tissues, organs, or organisms.
- the method involves delivering to said locus a disclosed Cas13 effector protein and one or more crRNA components (i.e., an RNA containing a crRNA), wherein the Cas13 protein forms an RNP complex with the one or more crRNAs components.
- the Cas13 effector protein Upon binding of the complex to the locus of interest, the Cas13 effector protein induces the modification of the target locus of interest depending on the Cas13’s activity.
- the modification is the introduction of a strand break (e.g., cleavage).
- the modification is a deamination of a target nucleotide.
- the complex can be formed in vitro or ex vivo and introduced into a cell or contacted with RNA; or can be formed in vivo.
- Cas13 is capable of robust RNA detection.
- Cas13 is converted to an RNA binding protein ("dead Cas13”) by inactivation of its nuclease activity. Converted to an RNA binding protein, Cas13 is useful for localizing other functional components to RNA in a sequence dependent manner.
- the components can be natural or synthetic.
- Dead Cas13 can be used to (i) bring effector modules to specific transcripts to modulate the function or translation, which could be used for large-scale screening, construction of synthetic regulatory circuits and other purposes; (ii) fluorescently tag specific RNAs to visualize their trafficking and/or localization; (iii) alter RNA localization through domains with affinity for specific subcellular compartments; and (iv) capture specific transcripts (through direct pull down of dead Cas13 or use of dead Cas13 to localize biotin ligase activity to specific transcripts) to enrich for proximal molecular partners, including RNAs and proteins.
- the small size of the mCas13 protein can allow easier packaging into commonly used delivery vectors, such as adeno- associated viruses (AAV) and thus easier delivery of this protein in vivo for various RNA targeting and manipulation as well as therapeutic applications.
- AAV adeno- associated viruses
- Such applications include, without limitation, RNA knockdown, RNA editing, antiviral activity, and RNA tagging and imaging.
- thermostable enzymes has allowed the development of various biotechnological applications at elevated temperature, such as, the development of nucleic acid detection methods.
- the thermophilic TccCas13a is useful in developing different detection modules for nucleic acids, and possibly other molecules.
- the disclosed TccCas13a protein allows for various RNA targeting and manipulation applications in various prokaryotic and eukaryotic organisms, such as RNA knockdown, RNA editing, antiviral activity, and RNA tagging and imaging.
- the robust thermostability of TccCas13a can also allow all of the aforementioned applications in thermophilic organisms. This is an advantage of TccCas13a over all other known Cas13 enzymes.
- both mCas13 and TccCas13 nucleic acid detection modules can be developed for the detection of other pathogens, including any DNA and RNA viruses, bacteria and others. A.
- RNA knockdown with Cas13 can be applied to perturbing RNAs in multiple biological contexts, including genome-wide pooled knockdown screening, interrogation of LincRNA and nascent transcript function, allele-specific knockdown, and RNA viral therapeutics.
- Such inhibitory effects i.e., targeted knockdown of an RNA transcript
- RNA transcript can be endogenous or exogenous to a cell.
- the RNA transcript can be coding (e.g., an mRNA) or non-coding (e.g., lincRNA).
- the RNA transcript is derived from a viral gene, such as a bacteriophage.
- the Cas13 compositions can be used to inhibit or reduce viral gene expression or viral replication.
- Current RNA knockdown strategies such as siRNA have the disadvantage that they are mostly limited to targeting cytosolic transcripts since the protein machinery is cytosolic.
- a Cas13 mediated knockdown is that it is an exogenous system that is not essential to cell function, and it can be used in any compartment in the cell.
- a NLS signal By fusing a NLS signal to the Cas13, it can be guided to the nucleus, allowing nuclear RNAs to be targeted, e.g., to probe the function of lincRNAs.
- Long intergenic non- coding RNAs (lincRNAs) are a vastly underexplored area of research. Most lincRNAs have as of yet unknown functions which could be studies using the RNA targeting effector protein of the invention.
- Knockdown of RNA transcript relies on cleavage of the targeted transcripts by the endogenous RNase activity of the dual HEPN domains of the Cas13 protein, the efficiency of which varies between different orthologs and subtypes of Cas13.
- modulation of cleavage efficiency can be exploited by introduction of mismatches, e.g., 1 or more mismatches, such as 1 or 2 mismatches between the spacer sequence and target sequence, including the position of the mismatch along the spacer/target.
- mismatches e.g., 1 or more mismatches, such as 1 or 2 mismatches between the spacer sequence and target sequence, including the position of the mismatch along the spacer/target.
- the more central (i.e., not 3' or 5') for instance a mismatch is, the more cleavage efficiency is affected.
- RNA imaging and/or localization Methods to monitor RNA trafficking are also provided.
- the Cas13 proteins can be used to effectively fluorescently tag specific RNAs to visualize their trafficking and/or localization.
- the Cas13 is preferably catalytically inactive (e.g., the Cas13 functions as an RNA binding protein without nuclease activity).
- the Cas13 can be linked (e.g., as a fusion protein with or without a linker) to a detectable marker.
- the Cas13-crRNA RNP targets and hybridizes to the targeted RNA transcript, thereby indicating the location and/or movement of the RNA transcript within the cell.
- Exemplary detectable markers that can be used to visualize the targeted RNA transcript include GFP, eGFP, RFP, YFP, BFP, CFP, mNeonGreen, mCherry, mOrange, mRaspberry, mPlum, mKO, mRFP, mRFPruby, mRuby, tagRFP, mKate2, and DsRed.
- the Cas13-crRNA RNP is capable of hybridizing with a region in an RNA transcript that contains an A nucleotide to be edited.
- the crRNA forms an RNA duplex with the RNA transcript wherein the duplex contains an A-C mismatch at the target A nucleotide resulting in the target A nucleotide being deaminated by the deaminase domain (resulting in A-I).
- Suitable deaminase domains include deaminase domains from ADAR1, ADAR2, and ADAR3, such as human ADAR1, ADAR2, and ADAR3.
- RNA isolation or purification, enrichment or depletion The Cas13 can be used as an RNA targeting effector protein when complexed to a target RNA to isolate and/or purify the target RNA.
- the Cas13 protein can for instance be fused to an affinity tag that can be used to isolate and/or purify the RNA-Cas13 protein complex. Such applications are for instance useful in the analysis of gene expression profiles in cells.
- the Cas13 proteins can be used to target a specific noncoding RNA (ncRNA) thereby blocking its activity, providing a useful functional probe.
- ncRNA noncoding RNA
- the Cas13 protein may be used to specifically enrich for a particular RNA (including but not limited to increasing stability, etc.), or alternatively to specifically deplete a particular RNA (such as without limitation for instance particular splice variants, isoforms, etc.).
- RNA binding proteins can be useful for understanding the roles of many RNAs. For instance, many lincRNAs associate with transcriptional and epigenetic regulators to control transcription. Understanding what proteins bind to a given lincRNA can help elucidate the components in a given regulatory pathway.
- a Cas13 effector protein can be designed to recruit a biotin ligase to a specific transcript in order to label locally bound proteins with biotin. The proteins can then be pulled down and analyzed by mass spectrometry to identify them.
- F. Detection of nucleic acids The Cas13 proteins can be used for detection of nucleic acids or proteins in a biological sample. The samples can be cellular or cell-free.
- the Cas13 protein can be used to specifically bind and detect the target RNA sequence.
- Cas13 protein complexes with the guide RNA via recognition of a short hairpin in the crRNA, and target specificity is encoded by the spacer that is complementary to the target region.
- all Cas13s exhibit “collateral activity” after recognition and cleavage of a target transcript, leading to non-specific degradation of any nearby transcripts regardless of complementarity to the spacer. This collateral activity can be referred to as trans activity because the Cas13 is activated to cleave other RNA species in trans without sequence specificity.
- the activity toward the targeted RNA transcript can be referred to as cis activity.
- the disclosed Cas13 based detection assay take advantage of this cis and trans Cas13 activity.
- Cas13 proteins such as mCas13, TccCas13a, and HheCas13a can cleave non-targeted single stranded RNA (ssRNA) once activated by detection of a target RNA.
- a type VI CRISPR/Cas effector protein e.g., mCas13, TccCas13a, or HheCas13a
- a crRNA which occurs when the crRNA hybridizes to a target sequence of a target RNA (i.e., the sample includes the targeted RNA)
- the protein becomes a nuclease that cleaves non-target ssRNAs (i.e., ssRNAs to which the spacer sequence of the crRNA does not hybridize).
- the result is cleavage of ssRNAs in the sample, which can be detected using any convenient detection method (e.g., using a labeled ssRNA oligonucleotide).
- a method of detecting the presence of an RNA transcript in a nucleic acid sample by contacting the sample with the Cas13 composition in the presence of an activatable single stranded RNA (ssRNA) oligonucleotide that includes a reporter moiety.
- the reporter moiety includes a fluorophore linked to a quencher via the ssRNA.
- Fluorescence can be emitted upon cleavage of the ssRNA oligonucleotide since the quencher is no longer in proximity to the fluorophore.
- the crRNA is designed to hybridize to the RNA transcript and the Cas13 cleaves the ssRNA oligonucleotide upon binding of the Cas13 crRNA complex to the RNA transcript. Detecting cleavage of the ssRNA oligonucleotide indicates the presence of the RNA transcript.
- the RNA transcript could have been generated by transcription from a dsDNA molecule, and in some embodiments, the dsDNA molecule could have been generated by reverse transcription coupled amplification of a target RNA.
- a Cas13-based method of detecting the presence of a nucleic acid in a sample involves (a) performing an amplification reaction (e.g., LAMP, RPA) on nucleic acids derived from the sample to generate a specific amplification product; (b) transcribing the amplification product to generate an RNA transcript; (c) contacting the RNA transcript with a Cas13-crRNA RNP complex having a crRNA complementary to the RNA transcript; in the presence of an activatable ssRNA oligonucleotide; and (d) detecting cleavage of the ssRNA oligonucleotide by the Cas13 enzyme.
- an amplification reaction e.g., LAMP, RPA
- transcription of the amplification product in step (b) is mediated by a T7 RNA polymerase in vitro.
- cleavage of the ssRNA oligonucleotide is dependent on or subsequent to binding of the RNP to the RNA transcript.
- cleavage of the ssRNA oligonucleotide results in release of a previously quenched fluorescent signal, thereby indicating the presence of the nucleic acid.
- the Cas13-based detection assay can be performed as a one-pot or two-pot assay depending on the Cas13 enzyme that is used.
- the assay can be performed as a one-pot assay in which isothermal amplification (e.g., LAMP, optionally coupled with reverse transcription (i.e., RT-LAMP)) of the target nucleic acids, coupled with T7-mediated in vitro transcription and Cas13- based detection of the amplified and in vitro-transcribed target RNA is carried out in the same tube.
- isothermal amplification e.g., LAMP, optionally coupled with reverse transcription (i.e., RT-LAMP)
- RT-LAMP reverse transcription
- mCas13 can be preferably used in a two-pot assay.
- the RT-LAMP reaction is performed in a first tube while T7- mediated in vitro transcription and mCas13-based detection of the amplified and in vitro-transcribed target RNA is performed in a second tube.
- the sample is or the nucleic acids are derived from mucus, sputum (processed or unprocessed), bronchial alveolar lavage (BAL), bronchial wash (BW), bodily fluids, cerebrospinal fluid (CSF), urine, tissue (e.g., biopsy material), rectal swab, nasopharyngeal aspirate, nasopharyngeal swab, throat swab, sputa/deep throat saliva, feces, mucosal excretions, plasma, serum, or whole blood.
- the sample is a nucleic acid isolated and/or derived from any of the foregoing biological samples.
- the methods may be used for any purpose for which detection of viral, bacterial or other nucleic acids is desirable, including diagnostic and prognostic applications, such as in laboratory and clinical settings.
- the methods may be used for detection of a nucleic acid for genotyping.
- the nucleic acid to be detected is diagnostic for a disease state.
- the disease state can be an infection, an organ disease, a blood disease, an immune system disease, a cancer, a brain and nervous system disease, an endocrine disease, a pregnancy or childbirth- related disease, an inherited disease, or an environmentally-acquired disease, cancer, or a fungal infection, a bacterial infection, a parasite infection, or a viral infection.
- the method is useful for detecting a nucleic acid (e.g., DNA or RNA) from a bacterium, fungus, virus, or parasite.
- viruses that can be detected include, without limitation, Myoviridae, Podoviridae, Siphoviridae, Alloherpesviridae, Herpesviridae (including human herpes virus, and Varicella Zozter virus), Malocoherpesviridae, Lipothrixviridae, Rudiviridae, Adenoviridae, Ampullaviridae, Ascoviridae, Asfarviridae (including African swine fever virus), Baculoviridae, Cicaudaviridae, Clavaviridae, Corticoviridae, Fuselloviridae, Globuloviridae, Guttaviridae, Hytrosaviridae, Iridoviridae, Maseilleviridae, Mimivi
- the virus is coronavirus (e.g., SARS-Cov-2), SARS, Poliovirus, Rhinovirus, Hepatitis A, Norwalk virus, Yellow fever virus, West Nile virus, Hepatitis C virus, Dengue fever virus, Zika virus, Rubella virus, Ross River virus, Sindbis virus, Chikungunya virus, Borna disease virus, Ebola virus, Marburg virus, Measles virus, Mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, Human respiratory syncytial virus, Rabies virus, Lassa virus, Hantavirus, Crimean-Congo hemorrhagic fever virus, Influenza, or Hepatitis D virus.
- coronavirus e.g., SARS-Cov-2
- SARS e.g., SARS-Cov-2
- SARS e.g., SARS-Cov-2
- Poliovirus Poliovirus
- Rhinovirus Hepatitis A
- Norwalk virus Yellow fever virus
- the nucleic acid to be detected can be associated with a pathogen, including pathogenic bacteria such as, E. faecalis, E. faecium Listeria monocytogenes, Campylobacter jejuni, Staphylococcus aureus (e.g., MRSA), E.
- pathogenic bacteria such as, E. faecalis, E. faecium Listeria monocytogenes, Campylobacter jejuni, Staphylococcus aureus (e.g., MRSA), E.
- compositions and methods can also be understood through the following numbered paragraphs: 1.
- a polynucleotide comprising a nucleotide sequence encoding a class II, type VI CRISPR/Cas effector protein (Cas13) and optionally a heterologous sequence, wherein the Cas effector protein comprises an amino acid sequence encoded by SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67, or a sequence with at least 70% sequence identity thereto; optionally wherein the sequence encoding the Cas effector protein comprises SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67, or a sequence with at least 70% sequence identity to SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67. 2.
- the polynucleotide of paragraph 1 or 2 comprising a heterologous sequence, wherein the heterologous sequence comprises a promoter, transcription terminator, multiple cloning site, drug resistance marker, one or more protease recognition sites, one or more epitope tags, or a combination thereof.
- the heterologous sequence is operably linked to the sequence encoding the Cas effector protein. 5.
- the polynucleotide of any one of paragraphs 1-4 further comprising a sequence encoding an RNA comprising a crRNA sequence, wherein the RNA is capable of complexing with the Cas effector protein and hybridizing to a target RNA sequence.
- the Cas effector protein is derived from Thermoclostridium caenicola or a Proteobacteria bacterium. 7.
- a vector comprising the polynucleotide of any one of paragraphs 1-6, optionally wherein the vector comprises the nucleotide sequence of SEQ ID NO:69 or SEQ ID NO:70, or a sequence having at least 60% sequence identity to SEQ ID NO:69 or SEQ ID NO:70.
- the vector of paragraph 7, wherein the vector is a viral vector or plasmid.
- a prokaryotic or eukaryotic cell comprising the vector of paragraph 7 or 8.
- a method of producing a class II, type VI CRISPR/Cas effector protein comprising contacting the vector of paragraph 7 or 8 with a prokaryotic or eukaryotic cell under conditions suitable for expression of the sequence encoding the Cas effector protein. 11.
- the method of paragraph 10 further comprising isolating and/or purifying the Cas effector protein.
- An isolated class II, type VI CRISPR/Cas effector protein wherein the Cas effector protein is produced by the method of paragraph 10 or 11.
- An isolated class II, type VI CRISPR/Cas effector protein comprising the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:66, or a sequence with at least 70% sequence identity to SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68.
- a ribonucleoprotein complex comprising the Cas effector protein of paragraph 12 or 13 complexed with an RNA comprising crRNA sequence, optionally wherein the RNA is capable of hybridizing to a target RNA sequence.
- a composition comprising a Cas13 protein, wherein the Cas13 protein comprises the amino acid sequence of SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68, or a sequence with at least 70% sequence identity to SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68.
- the Cas13 protein comprises one or more HEPN (Higher Eukaryotes and Prokaryotes Nucleotide-binding) domains, preferably two HEPN domains.
- the HEPN domain comprises a RxxxxH (SEQ ID NO:192) motif sequence, wherein X represents any amino acid. 18.
- the crRNA sequence comprises a spacer sequence that is capable of hybridizing to the target RNA sequence, and a direct repeat sequence.
- the crRNA sequence comprises a spacer of about 20-30 nucleotides, preferably 24-28 nucleotides. 21.
- composition of any one of paragraphs 18-20, wherein the Cas13 protein can cleave the target RNA sequence at a temperature of about 37-70 o C, about 50-70 o C, about 47-60 o C, or about 60 oC. 22.
- the composition of any one of paragraphs 18-20, wherein the Cas13 protein can cleave the target RNA sequence at a temperature of about 37 o C-42 °C, preferably about 37 o C. 23.
- the composition of any one of paragraphs 18-22 comprised in a prokaryotic or eukaryotic cell. 24.
- a method of performing targeted knockdown of an RNA transcript comprising introducing the composition of any one of paragraphs 18-22 to a cell, wherein the crRNA sequence hybridizes to the RNA transcript, thereby inducing cleavage of the RNA transcript by the Cas13 protein.
- RNA transcript is a mRNA or lincRNA.
- RNA transcript is derived from a viral gene, preferably a bacteriophage. 27.
- a method of detecting the presence of an RNA transcript in a nucleic acid sample comprising contacting the sample with the composition of any one of paragraphs 18-22 in the presence of an activatable single stranded RNA (ssRNA) oligonucleotide comprising a reporter moiety, wherein the crRNA is designed to hybridize to the RNA transcript, wherein the Cas13 cleaves the ssRNA oligonucleotide upon binding of the Cas13 crRNA complex to the RNA transcript, wherein detection of the cleavage of the ssRNA oligonucleotide indicates the presence of the RNA transcript.
- ssRNA activatable single stranded RNA
- RNA transcript is generated by transcription from a dsDNA molecule, optionally wherein the dsDNA molecule is generated by reverse transcription coupled isothermal amplification of a target RNA.
- the reporter moiety comprises a fluorophore linked to a quencher via the ssRNA, wherein fluorescence is emitted upon cleavage of the ssRNA oligonucleotide.
- a method of determining the localization of an RNA transcript in a cell comprising introducing the composition of any one of paragraphs 18-22 to the cell, wherein the Cas13 is catalytically inactive and further comprises a detectable marker, wherein the crRNA is designed to hybridize to the RNA transcript, and wherein the Cas13 crRNA complex binds to the RNA transcript, thereby indicating the location of the RNA transcript.
- the detectable marker is selected from GFP, eGFP, RFP, YFP, BFP, CFP, mNeonGreen, mCherry, mOrange, mRaspberry, mPlum, mKO, mRFP, mRFPruby, mRuby, tagRFP, mKate2, and DsRed. 32.
- a method for performing targeted editing of an RNA transcript comprising introducing the composition of any one of paragraphs 18-22 to a cell, wherein the Cas13 is catalytically inactive and further comprises a deaminase domain of an RNA-dependent Adenosine Deaminase (ADAR), wherein the crRNA is capable of hybridizing with a region in the RNA transcript comprising a target A nucleotide to form an RNA duplex, wherein the duplex comprises an A-C mismatch at the target A nucleotide, wherein the target A nucleotide is deaminated by the deaminase domain.
- ADAR RNA-dependent Adenosine Deaminase
- Example 1 Development of a Cas13-based, one-pot assay for SARS- CoV-2 detection. This Example reports the identification and characterization of a thermostable Cas13a ortholog from Thermoclostridium caenicola (TccCas13a) that is highly active at high temperatures required for some amplification methods, such as RT-LAMP.
- TccCas13a thermostable Cas13a ortholog from Thermoclostridium caenicola
- thermophilic Cas13a orthologues including Cas13a from Herbinix hemicellulosilytica (HheCas13a) also exhibited strong activity at elevated temperatures. These Cas13s were characterized with regards to temperature, reporter cleavage preference and optimal reaction conditions.
- RT-LAMP utilizing a SARS-CoV-2 N-gene specific primer set with FIP primer carrying a T7 promoter was coupled to in vitro transcription mediated by the thermostable Hi-T7 RNA polymerase and the reaction conditions were optimized for one-pot detection assay. The data described below demonstrates that this protocol can robustly detect SARS-CoV-2 in clinical samples derived from COVID-19 patients.
- thermophilic Cas13-based one-pot detection assay holds great promise for use as a prospective POC modality to help address increased demand for SARS-CoV-2 testing.
- Materials and Methods Computational identification of a thermophilic CRISPR/Cas13a
- Various existing Cas13 enzymes and their bacterial hosts were manually interrogated to identify potential thermophilic Cas13s originating from thermophilic organisms.
- the protein sequence of HheCas13a was used as a query in the Basic Local Alignment Search Tool (BLAST) against the NCBI non-redundant (nr) protein database using default settings.
- BLAST Basic Local Alignment Search Tool
- TccCas13a protein (accession# WP_149678719.1) from Thermoclostridium caenicola was identified as a potential thermophilic Cas13 protein.
- Phylogenetic tree was reconstructed using protein sequences of different Cas13s belonging to different families/subtypes of Class II/type VI CRISPR-Cas systems. All protein sequences were organized in a single .txt file and aligned using MUSCLE in MEGAX software with default settings.
- the phylogenetic reconstruction was based on the Maximum-Likelihood method using MEGAX with WAG+G+F model and 1000 bootstrap samplings.
- the generated output file (.nwk) was visualized using TreeGraph_2.
- CRISPRCasFinder [1] was performed on the genomic DNA sequence (GenBank# NZ_FQZP01000023.1) to identify the associated CRISPR array.
- CRISPRDetect [2] was then used to predict the orientation of the direct repeat in the TccCas13a CRISPR array.
- the expression vector for HheCas13a “p2CT-His-MBP- Hhe_Cas13a_WT” was obtained from Addgene (plasmid #91871), and the purification of HheCas13a was performed following a previously published protocol [10].
- the E. coli codon-optimized TccCas13 coding sequence was synthesized (GenScript) de novo and subcloned in frame with His and SUMO tags on the N-terminus into the His6-TwinStrep-SUMO bacterial expression vector (Addgene #115267) using BamHI and NotI (Table 4).
- TccCas13a protein Purification of TccCas13a protein was performed following the protocol of Kellner et al. (2019) [20] with a few modifications. Briefly, the TccCas13a expression vector was transformed into BL21 E. coli cells. Starter cultures were prepared by growing single colonies in LB broth supplemented with 100 ⁇ g/mL ampicillin for around 12 h at 37 °C. Next, 25 mL of starter culture was used to inoculate 1 L of Terrific Broth medium (TB) (IBI scientific) supplemented with 100 ⁇ g/mL ampicillin, and the 1 L cultures (4 L total) were incubated at 37 °C until an OD600 of 0.5.
- TB Terrific Broth medium
- Cells were incubated at 4°C 30 mins, and the expression was induced with 0.5 mM IPTG. Cultures were then incubated at 16 °C at 180 rpm for overnight expression. Next, cells were harvested by centrifugation for 20 min at 4 °C at 4000 rpm. Cell pellets were resuspended in lysis buffer (50 mM Tris-Cl pH 7.5, 300 mM NaCl, 5% glycerol, 1 mM TCEP, 4.5 mM MgCl2, 1 mM PMSF, EDTA-free protease inhibitor (Roche)) and supplemented with 1 mg/mL lysozyme (L6876, Sigma).
- lysis buffer 50 mM Tris-Cl pH 7.5, 300 mM NaCl, 5% glycerol, 1 mM TCEP, 4.5 mM MgCl2, 1 mM PMSF, EDTA-free protease inhibitor (Roche
- Cleaved protein was concentrated to 1.5 mL by Amicon Ultra-15 Centrifugal Filter Units (100 kDa NMWL, UFC905024, Millipore) and further purified via size- exclusion chromatography on a S200 column (GE Healthcare) in gel filtration buffer (50 mM Tris-HCl, 200 mM KCL, 10% glycerol, 1 mM TCEP, pH 7.5). The protein-containing fractions resulting from the gel filtration were pooled, snap frozen, and stored at -80 °C.
- Nucleic acid preparation A short region of the SARS-CoV-2 N gene sequence was used as the target sequence in all preliminary thermophilic Cas13 characterization and optimization experiments to screen collateral reporters and assess thermostability of Cas13 proteins.
- the N gene target RNA sequence was prepared by in vitro transcription of PCR amplicons containing the T7 promoter sequence using the 2019-nCoV_N_Positive Control plasmid as a PCR template (10006625, IDT) (primers used are listed in table 2). Purified PCR amplicons (QIAquick PCR Purification Kit, QIAGEN) were transcribed in vitro using HiScribe T7 Quick High Yield RNA Synthesis Kit (E2050, NEB).
- HheCas13a and TccCas13a crRNAs were designed to target the N gene sequence of the SARS-CoV-2 genome.
- templates for in vitro transcription were generated using single-stranded DNA oligos containing a T7 promoter, scaffold, and spacer in reverse complement orientation (IDT), and were then annealed to T7 forward primer in Taq DNA polymerase buffer (Invitrogen) (Table 5). The annealed oligos were then used as templates for the subsequent in vitro transcription as described above.
- thermophilic Cas13-based one-pot assay control synthetic SARS-CoV-2 viral genomic sequences were ordered as synthetic RNA from Twist Bioscience, and were diluted to 10,000 RNA copies/ ⁇ L and used at indicated concentrations.
- RT-LAMP amplification previously published LAMP primers designed to amplify the SARS- CoV-2 N gene (Joung et al., 2020 [12], Broughton et al., 2020 [4]) were used, with the following modifications.
- the FIP or BIP primers were designed with the T7 promoter sequence appended at the 5' end of the first half of the primers (Table 1).
- Differential scanning fluorimetry DSF was performed using 5 to 15 uM of the purified Cas13 proteins in gel filtration buffer (with 5% glycerol) containing 10% SYPRO Orange fluorescent dye (ThermoFisher, S6650) in final reaction volume of 35 uL. Proteins were tested in triplicates and the fluorescence was monitored using a 96-well Real-Time PCR detection system (CFX96 qPCR machine, Bio- Rad), from 25 to 95 °C, with a gradual temperature increase of 1 °C every 10 s.
- CFX96 qPCR machine 96-well Real-Time PCR detection system
- Protein thermostability assay LwaCas13a, HheCas13a and TccCas13a proteins were diluted to approximately 0.2 mg/mL in protein storage buffer (50 mM Tris-HCL pH 7.5, 600 mM NaCl, 5% glycerol, 2 mM DTT) and incubated at a range of temperatures (37, 60, 70 and 90°C) for 30 minutes. Samples were spun down in a microcentrifuge at 14200 rpm for 25 minutes. A total of 5 ⁇ L of the supernatant was mixed with the same volume of protein sample loading buffer and heated at 95°C for 10 minutes.
- protein storage buffer 50 mM Tris-HCL pH 7.5, 600 mM NaCl, 5% glycerol, 2 mM DTT
- cleavage reactions were carried out in 20 ⁇ L reaction volume with 50 nM of Cas13a protein, 50 nM of their cognate crRNAs, and 100 nM of target RNA in 1x isothermal buffer (20 mM Tris-HCl, 50 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , 0.1% Tween 20, pH 8.8) supplemented with additional 6 mM MgSo4 (final of 8 mM MgSo2), and the reactions were then incubated at the indicated temperatures for 1 hr (no pre-assembly of Cas13a protein and crRNA to form RNP was performed).
- the samples were then boiled at 70°C for 3 minutes in 2X RNA Loading Dye (NEB, B0363S) and cooled on ice for 3 minutes before loading into 6% polyacrylamide-urea denaturing gel.
- the electrophoresis was run for 45 minutes at 25W.
- the gel was stained with SYBRTM Gold Nucleic Acid Gel Stain (ThermoFisher, S11494) for 10 minutes, briefly washed with 1X TBE buffer and visualized using Bio-Rad Molecular Imager ⁇ Gel Doc ⁇ system.
- Fluorescent ssRNA cleavage assays For all reporter screening and thermostability assays, 50 nM of HheCas13a or TccCas13a proteins were incubated with 50 nM of the respective crRNAs, 250 nM of ssRNA reporter (either poly A, poly U, or mixed sequence reporter) in 1X isothermal buffer (20 mM Tris-HCl, 50 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Tween 20, pH 8.8) supplemented with additional 6 mM MgSo4 (final of 8 mM MgSo2), 0.8 U/uL RNaseOUT (10777019, Invitrogen) and 2 uL of (1-100 nM) of target RNA in 20 uL reaction volume.
- 1X isothermal buffer (20 mM Tris-HCl, 50 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4,
- the reaction was performed using RT-LAMP primers with final concentrations of 1.6 ⁇ M FIP/BIP primers (with the T7 promoter sequence fused to either the FIP or BIP primer), 0.2 ⁇ M F3/B3 primers, and 0.4 ⁇ M LF/LB primers, 1X Isothermal Amplification Buffer (from different vendors in Bst DNA polymerase screening reactions) or from Lucigen (30027, Lucigen) in other optimization experiments), 1.4 mM dNTPs, 0.32 U/uL Bst DNA Polymerase (from different vendors in Bst DNA polymerase screening reactions) or from Lucigen (30027, Lucigen)), 0.45 U/uL of WarmStart RTx Reverse Transcriptase (M0380, NEB) or 2 U/ uL SuperScript IV reverse transcriptase (18090010, Invitrogen), 6 mM MgSO 4, 0.1 U/uL thermostable RNAseH ( M0523S, NEB), 0.8 U/
- SEQ ID Nos:9-16 were used in Example 1.
- SEQ ID Nos:1-16 were used in Example 2.
- Table 2 Primers to PCR amplify N gene regions for IVT in Examples 1 and 2.
- Table 3 RNA reporter designs and sequences used in in Examples 1 and 2.
- Table 4 Cas13 protein sequence used in this study. 6x His affinity tag: residues 5-10; Thrombin site: residues 14-19; Strep-tag II: residues 24-31 and 44-51; SUMO: residues 52-148; TccCas13a protein: residues 151-1375. For HheCas13 sequence (Ref [10]). Table 5: crRNA sequences used in this study.
- OPTIMA-dx reaction The reaction was performed using RT-LAMP primers at a final concentration of 1.6 ⁇ M FIP/BIP primers (with the T7 promoter sequence added to the FIP primer), 0.2 ⁇ M F3/B3 primers, and 6420.4 ⁇ M LF/LB primers, in 1X Isothermal Amplification Buffer from Lucigen (30027, Lucigen), 1.4 mM dNTPs, 2.4 U/ ⁇ L Bst DNA Polymerase (30027, Lucigen), 0.3 U/ ⁇ L of WarmStart RTx Reverse Transcriptase (M0380, NEB), 6 mM MgSO 4 , 0.8 U/ ⁇ L RNasin plus (N2611, Promega), 0.5 mM NTPs, 4 U/ ⁇ L Hi-T7 RNA polymerase (M0658S, NEB), 0.4 U/ ⁇ L thermostable inorganic pyrophosphatase (M0296, NEB), 1 ⁇ M s
- Adetailed protocol for the OPTIMA-dx reaction setup is provided in supplementary note 1.
- One-pot multiplexed OPTIMA-dx reaction The multiplexed reaction was performed as described above (OPTIMA-dx reaction) with the following modification. 50 nM of AapCas12b protein, 50 nM of AapCas12b sgRNAs-1 for RNase P detection, 250 nM HEX ssDNA reporter (the FAM reporter used at 250 nM instead of 1 ⁇ M in multiplexed detection), and RT-LAMP primers for RNase P detection (LF and LB were 655 used at 0.2 ⁇ M final concentration) were added to OPTIMA-dx SARS-CoV-2 or HCV detection 656 components.
- the final reaction volume is 50 ⁇ L. These reactions were incubated in a 96-well 657 plate (BioRad) at 56°C for 1–2 h in a 96- well Real-Time PCR detection system (CFX96 qPCR 658 machine, Bio- Rad), with fluorescence measurements taken every 2 min using both FAM and 659 HEX channels.
- Pre-crRNA processing assays RNA oligos of 5′ FAM-labelled pre-crRNAs were custom- synthesized (IDT). Pre-crRNA processing assays were performed in 1x isothermal buffer (B0537, NEB) supplemented with an additional 6 mM MgSO4 (final of 8 mM MgSO4) in a 20- ⁇ L reaction volume.
- Reverse transcription and LAMP isothermal amplification of target nucleic acids were conducted using the previously reported RT-LAMP primers [Joung N Engl J Med, 2020.383(15): p.1492-1494]. Reactions were performed using 1.6 ⁇ M FIP/BIP primers (with the T7 promoter sequence added to either the FIP or BIP primer), 0.2 ⁇ M F3/B3 primers, and 0.4 ⁇ M LF/LB primers in 1X Isothermal Amplification Buffer (20 mM Tris- HCl pH 8.8, 50 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Tween 20) (B0537, NEB), 1.4 mM dNTPs, 8 U of Bst 2.0 WarmStart DNA Polymerase (M0538, NEB), 7.5 U of WarmStart RTx Reverse Transcriptase (M0380, NEB) and 6 mM MgSO4
- the reporter cleaved by TccCas13a is the reaction product in this assay.
- 0.5 nM of activated RNP was treated with different concentrations of FAM Mix reporters.
- 100 nM RNP was first prepared by incubating 100 nM TccCas13a protein, 125 nM crRNA (# 1172), and 1 U of RNase inhibitor (NEB, M0314L) in 1X isothermal amplification buffer (B0537, NEB) supplemented with 6 mM MgSO4 at 56°C for 10 minutes.
- the trans cleavage activity of RNP was activated by mixing 20 nM of N gene target with 2 nM RNP in 1 x isothermal amplification buffer supplemented with 6 mM MgSO4 and 1 U of RNase inhibitor and incubated at 56°C for 15 min.
- FAM Mix reporter at concentrations of 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, 1 ⁇ M, 2 ⁇ M and 4 ⁇ M was added into 0.5 nM of target- activated RNP together with 6 mM MgSO4 and 1 U of RNase inhibitor in 1x isothermal amplification buffer in 20 ⁇ L of the final volume.
- the fluorescence readout was measured every 30 s at 56°C (CFX96 qPCR machine, Bio-Rad). The same reactions described above were also carried out in parallel without the addition of crRNA, which were used as controls to subtract the fluorescence background signal. The data were analyzed by GraphPad Prism software (GraphPad, CA, USA) to calculate KM and kcat. First, the data obtained from reactions without crRNA were subtracted from those reactions with crRNA to obtain the true fluorescence generated by enzyme-cleaved reporters. The real-time data from the first 600 s were fitted using linear regression to obtain the initial reaction velocity for different reporter concentrations represented by the increase of fluorescence over time, which can be represented as dF/dt.
- FAM Mix at 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, 1 ⁇ M, and 2 ⁇ M was incubated with 40 ⁇ g of RNase A (Invitrogen, cat: 12091-039) in 20 ⁇ L reaction at 37°C for more than 3 hours to ensure complete cleavage.
- RNase A Invitrogen, cat: 12091-039
- reaction velocity dP/dt over reporter concentration was fitted to the Michaelis ⁇ Menten equation to calculate the value of KM and Vmax.
- the kcat can be calculated as Vmax equals the value of kcatE0.
- the back- of-the-envelope test introduced in Ramachandran et al. [Ramachandran, et al., Anal Chem, 2021. 93(20): p.7456-7464] was conducted. For all the tests, an initial linear time portion tlin of 600 s was used to calculate the ⁇ , ⁇ , and ⁇ values:
- Reactions were performed using RT-LAMP primers at a final concentration of 1.6 ⁇ M for FIP/BIP primers (with the T7 promoter sequence added to either the FIP or BIP primer), 0.2 ⁇ M F3/B3 primers, and 0.4 ⁇ M LF/LB primers, in 1X Isothermal Amplification Buffer (from a different vendor from the Bst DNA polymerase screening reactions) or from Lucigen (30027, Lucigen) in other optimization experiments, 1.4 mM dNTPs, 0.32 U/ ⁇ L Bst DNA Polymerase (from a different vendor from the Bst DNA polymerase screening reactions) or 2.4 U/ ⁇ L from Lucigen (30027, Lucigen), 0.3 U/ ⁇ L of WarmStart RTx Reverse Transcriptase (M0380, NEB), 6 mM MgSO4, 0.8 U/ ⁇ L RNasin plus (N2611, Promega), 0.5 mM NTPS, 2 U/ ⁇ L Hi-T
- RT-LAMP primers All RT-LAMP primers are listed above. Screening of AapCas12b sgRNAs in one-pot reaction Reactions were performed using RT-LAMP primers at a final concentration of 1.6 ⁇ M for FIP/BIP primers, 0.2 ⁇ M F3/B3 primers, and 0.2 ⁇ M LF/LB primers, in 1X Isothermal Amplification Buffer (30027, Lucigen), 1.4 mM dNTPs, 2.4 U/ ⁇ L Bst DNA Polymerase (30027, Lucigen), 0.3 U/ ⁇ L of WarmStart RTx Reverse Transcriptase (M0380, NEB), 6 mM MgSO4, 0.8 U/ ⁇ L RNasin plus (N2611, Promega), 0.5 mM NTPS, 4 U/ ⁇ L Hi-T7 RNA polymerase (M0658S, NEB), 0.4 U/ ⁇ L thermostable inorganic pyrophosphatas
- Oropharyngeal and nasopharyngeal swabs were collected from suspected COVID-19 patients by physicians in Ministry of Health hospitals in Saudi Arabia and placed in 2-mL screw-capped cryotubes containing 1 mL of TRIZOL for inactivation and transport. Each sample tube was sprayed with 70% ethanol, enveloped with absorbent tissues, and then placed and sealed in individually labeled biohazard bags. The bags were then placed in leak-proof boxes and sprayed with 70% ethanol before placement in a dry ice container for transfer to the lab.
- beads were prepared by washing 1 mL of Sera-Mag SpeedBeads Carboxyl Magnetic Beads Hydrophobic (GE Healthcare 65152105050250) with 1 mL of UltraPure DNase/RNase-free distilled water (1097705, Invitrogen) twice and then resuspended in 50 mL of beads binding buffer (10 mM Tris-HCl pH 8.0, 1M KCl, 18 % PEG-8000, and 1mM EDTA).
- extraction mixture 50 mL was prepared by mixing 32.5 mL of beads (resuspended in binding buffer), 12.5 ml of 4x Viral RNA Extraction Buffer (VRE100, Sigma- Aldrich), and 5 mL of UltraPure DNase/RNase-free distilled water.
- the extraction mixture was aliquoted in 1.5 mL tubes, 400 ⁇ L each.
- 200 ⁇ L of VTM of oropharyngeal swabs were transferred into 400 ⁇ L of extraction mixture, vortexed vigorously and incubated at room temperature for 5 min. The mixture was then placed on a magnetic rack (Invitrogen DYNAL bead Separator) for 2-3 mins until the solution gets clear.
- VTM spiked with non-infectious virus particles 200 ⁇ L of VTM of oropharyngeal swabs collected from healthy donors were spiked with the indicated concentration of non-infectious virus particles (NATSARS(CoV2)-ERC, ZeptoMetrix) or with 200 ⁇ L of (NATSARS(CoV2)-NEG, ZeptoMetrix) for negative controls, and the spiked VTM were processed as described above.
- Real-time reverse transcription PCR for detecting positive SARS-CoV-2 RNA samples.
- RT-PCR was conducted on extracted RNA samples using the oligonucleotide primer/probe (Integrated DNA Technologies, 641 catalog #10006606) and Superscript III one-step RT-PCR system with Platinum Taq Polymerase (catalog #12574-026) following the manufacturer’s protocol. Freeze-drying of detection reactions Multiplexed OPTIMA-dx detection reactions were assembled as described above in a final volume of 50 ⁇ L in 1.5 mL tubes.
- Reactions were snap-frozen in liquid nitrogen and transferred to a LABCONCO Acid- Resistant CentriVap Concentrator (supplemented with LABCONCO CentriVap -105°C Cold Trap and Vacuubrand CVC 3000 Vacuum pump) Freeze Dry System for 2–3 hours of freeze-drying at a minimal temperature under the pressure of 1 to 10 millibar until the water was completely removed. Rehydration of freeze-dried reactions was accomplished with the RNA isolated from clinical samples (20 ⁇ L), 25 H2O, and 5 ⁇ L of 10X Isothermal Amplification Buffer from Lucigen (30027, Lucigen). Assembly of OPTIMA-dx reaction.
- TccCas13a protein Dilute TccCas13a protein into 1 ⁇ M in 1x isothermal buffer (Lucigen, 30027).2- Assemble TccCas13a RNP as follows: 3- Keep the assembly at room temperature while assembling the OPTIMA-dx reaction. 4- Assemble OPTIMA-dx master mix as follows:
- OPTIMA-dx Software Implementation
- the dataset of fluorescent images used for training the software consisted of many random images annotated manually as positive or negative to set the proper fluorescence intensity threshold.
- the software was then trained and tested multiple times to reach the best mean average precision (mAP) value with this dataset.
- the application allows the user to easily take a picture of PCR strips or upload an already captured image of a PCR strip illuminated by a transilluminator.
- the software determines the location of each tube, calculates a probability score for each target category and classifies each tube as positive (green bounding box) or negative (red bounding box) samples based on the intensity of the fluorescent signal (Fig.6d).
- the entire image processing, from capturing the reaction tubes to the final app output results, takes less than 1 min.
- Deep Learning Framework As of today, there are various deep learning frameworks for engineers and researchers to choose to train machine learning models [Abadi, M., et al., arXiv preprint arXiv:1603.04467, 2016, Chen, T., et al., Mxnet: arXiv preprint arXiv:1512.01274, 2015, Jia, Y., et al. Caffe: Convolutional architecture for fast feature embedding. in Proceedings of the 22nd ACM international conference on Multimedia.2014, Paszke, A., et al., Pytorch: An imperative style, high-performance deep learning library.
- TensorFlow is one of the most popular frameworks in deep learning community [Abadi, M., et al., arXiv preprint arXiv:1603.04467, 2016].
- TensorFlow-Lite (TensorFlow Lite. tensorflow.org/lite.) is the lightweight version of TensorFlow, which is specifically designed for the mobile 131 45497470v1
- Object Detection Model Object detection has been witnessing a rapid revolutionary change in the field of computer vision. Basically, it involves two tasks: Object localization: determine where objects are located in a given image. Specifically, object detection model will use rectangular bounding boxes to locate all the detected objects in the image. Object classification: determine which category each detected object belongs to. Specifically, for each detected object, object detection model will calculate a probability for each target category, indicating how likelihood this detected object be- longs to this specific category.
- SSD-Mobilenet-V2 combines the advantages of the two models, enabling it to efficiently perform target detection tasks on mobile devices. Transferring well-trained object detection models on one dataset to another new dataset is a common approach called transfer learning. It has several benefits, but the main advantages are saving training time, getting better performance, and not needing a lot of data.
- Google has trained one SSD- MobileNet-V2 object detection model using COCO dataset (Microsoft. https://cocodataset.org.), which has 90 different categories. This pre-trained model can be used as a good starting point for OPTIMA-dx detection model to help us save time and get better performance. Specifically, since this project only has 2 categories (positive and negative), final layers were 133 45497470v1
- OPTIMA-dx image dataset was created using P51TM Molecular Fluorescence Viewer (minipcr. https://www.minipcr.com/product/p51- molecular-glow-lab). Specifically, cameras were used on different mobile devices to take pictures of the tubes shown on this device. At least 391 pictures have been directly taken from mobile device cameras. When taking these pictures, due to some random lighting, angles, jitter and other issues, some pictures are distorted and blurred, which are not suitable for training and testing the model, and need to be deleted. These images were further augmented by randomly modifying the brightness, contrast, color and sharpness, which generated a new set of images.
- Model training In order to transfer visual knowledge learned from the large-scale generic dataset COCO to the model, it was initialized using Google’s pre- trained SSD- Mobilenet-V2. The model was then trained using the training set. Specifically, it was trained on one GeForce GTX 1080 Ti GPU with batch size 10. RMSprop optimizer was used with initial learning rate as 0.004.
- the TensorFlow Lite model can output 3 different kind of information: 1) the location of the bounding box for each detected tube, containing four coordinate values on the image plane: left, top, right and bottom.2) Category for each detected tube and its value is either positive or negative.3) One confidence score indicating the probability that the model thinks one tube belongs to the category. Finally, the bounding boxes, categories and confidence scores are drawn over the input image and display the final image on screen.
- the code for the smart phone app and to download the app is available at: hi- zhengcheng.github.io/optima-dx Results
- RT- LAMP Reverse transcription loop-mediated isothermal amplification
- RT-LAMP when used independently as a method to detect nucleic acids, it suffers from a high rate of false positives due to primer-dimer formation and cross- contamination. In order to address these drawbacks, introducing additional level of specificity is highly desirable. Coupling RT-LAMP to specific CRISPR/Cas target recognition and in trans reporter cleavage ensures signal appearance only in reactions where a correct amplicon has been generated. Nevertheless, most methods reported to date rely on transferring RT-LAMP 135 45497470v1
- thermostable reagents are needed that can tolerate the relatively high temperatures needed for the RT- LAMP reactions. Identification, screening and characterization of thermophilic Cas13 enzymes Recently, Cas13 variants from mesophilic bacteria have been employed for biosensing, including pathogen detection, genotyping, and diagnostics of viruses and disease markers. The SARS-CoV-2 pandemic highlighted the need to develop POC diagnostics. RT-LAMP is a practical approach for POC diagnostics.
- the current Cas13 homologs can only be used in a two-pot assay which is problematic and poses a risk of cross- contamination. Therefore, it was aimed to identify Cas13 proteins from thermophilic bacteria and test their thermostability in a wider temperature range especially at higher temperatures suitable for developing one-pot RT- LAMP assay involving virus genome amplification and CRISPR-mediated detection in a single tube. Cas13 variants were interrogated to determine whether some of these originate from thermophilic hosts.
- HheCas13a originating from Herbinix hemicellulosilytica thermophilic bacterium was identified as a potential thermophilic protein. Subsequently, the HheCas13a (1285 amino acids) was used as a query in BLAST-P NCBI searches of non-redundant protein sequences datasets to interrogate databases for potential thermophilic Cas13 homologs. A TccCas13 homolog originating from Thermoclostridium caenicola, sharing 87% identity at the amino acid level, was identified a as another likely thermophilic protein. The gene sequence of TccCas13a was 136 45497470v1
- TccCas13a In silico prediction of the TccCas13a crRNA was performed and the recently reported crRNA of the HheCas13a was used. TccCas13a and HheCas13a were incubated with and without their respective in vitro transcribed sgRNAs at 37, 60, 70 and 90°C for 30 minutes. The SDS-PAGE analysis demonstrated that the TccCas13a and HheCas13a loaded with sgRNA exhibit higher thermostability. However, TccCas13a exhibited a better thermostability compared to HheCas13a.
- thermostability e.g., one-pot RT-LAMP for diagnostic applications as well as targeted gene knockdown, virus interference, and RNA editing and imaging.
- Characterization of the cis and trans catalytic activities of the TccCas13a and HheCas13a thermophilic proteins The data showed that both proteins remain folded at higher temperatures and that loading of sgRNA enhances the thermostability of the proteins.
- sgRNAs were designed to cleave a synthetic target sequence to determine the ability of both proteins to exhibit catalytic cis activities at higher temperatures. 137 45497470v1
- thermophilic Cas13 enzymes namely HheCas13a and TccCas13a
- HheCas13a and TccCas13a
- RNP Cas13/crRNA ribonucleoproteins
- Such collateral activity has been harnessed in nucleic acid detection applications, where a ssRNA probe (reporter) molecule present in the Cas13 reaction is degraded by target-dependent Cas13 collateral activity [7].
- the ssRNA reporter contains a fluorophore linked by a short ssRNA sequence to a quencher, which emits fluorescence after the ssRNA sequence is cleaved, indicating the presence, and therefore the detection, of the target of interest. Because different Cas13 proteins exhibit different cleavage preferences depending on ssRNA sequences [6], the ssRNA reporter that can be cleaved by TccCas13a and HheCas13a effectors was investigated. It was determined whether these proteins retain the non-specific trans degradation activities of ssRNA reporter molecules in the presence of ssRNA target at higher temperatures.
- TccCas13a exhibited a trans-ssRNA cleavage preference against a mixed RNA sequence (not homopolymer ssRNA sequence) containing different nucleotides: UGACGU (FIG.1A).
- HheCas13 exhibited a cleavage preference for a homo-uridine ssRNA substrate, consistent with previous 138 45497470v1
- TccCas13a maintained a robust activity at temperatures as high as ⁇ 70 oC (Fig.2C).
- crRNAs with increased spacer lengths was tested using 24 and 28 nt long spacers.
- trans cleavage activity assays using a broad temperature range (37-72C) was conducted. The data showed that TccCas13a loaded with crRNA2 is active over a wide range of temperature (37-70C). HheCas13, however, showed, robust activity between 37-60C.
- TccCas13a showed comparable activity using 24 or 28 nt long spacer sequences (Fig.2D). These data provide compelling evidence on the thermostability and catalytic activities of TccCas13a and HheCas13a proteins and their usefulness in applications requiring cis and trans catalytic activities. See also Figs.1C-1E, 1F, and 2E. 139 45497470v1
- thermostable TccCas13a and HheCas13a To further characterize the activity of the identified thermostable Cas13 proteins, the crRNA requirements were tested by introducing various modifications to the crRNA spacer sequences. The effect of single mismatches between crRNA and target RNA on HheCas13a and TccCas13a RNA detection activities was tested. Single bases across the crRNA spacer sequence were mutated to the respective complementary bases. Results show that both HheCas13a and TccCas13a were tolerant to single mismatches across the spacer, as such mismatched spacers enabled RNA detection with similar efficiency as fully matched spacers (Fig.14A and Fig.14F).
- TccCas13a the ability of TccCas13a to process pre-crRNAs in vitro was investigated.
- pre-crRNA processing activity of TccCas13a was tested in comparison to HheCas13a and LwaCas13a proteins.
- LwaCas13a exhibited robust pre-crRNA processing activity, but HheCas13a did not process the cognate pre-crRNA when it was incubated at 37 or 60 °C, [10].
- thermostable HheCas13a and TccCas13a enzymes are the only pre-crRNA processing defective Cas13 homologs known to date, pointing to a possible relationship between the thermostability of these Cas13 variants and the lack of pre- crRNA processing activities.
- the robust activity of TccCas13a observed in the previous experiments led to further study the enzyme kinetics.
- thermophilic Cas13s for SARS-CoV-2 detection in one-pot and two-pot assays To ensure sensitive detection, pre-amplifying the RNA target of interest is a necessary step [7].
- RT-LAMP isothermal amplification was chosen because it possesses several advantages over other amplification methods, including high sensitivity, rapid turnaround time, simple operation, and low cost [11].
- Primer sets well-established in previous reports were used to target and amplify conserved regions in the SARS-CoV-2 N gene, named here as STOPCovid (SC) primer sets [4, 12]. However, because Cas13s target RNA, these primers were modified by appending a T7 promoter 141 45497470v1
- the T7 promoter sequence should get integrated into the amplified DNA products, providing a suitable template for the T7 RNA polymerase to transcribe the amplified LAMP product in vitro and generate RNA targets for Cas13 detection (Table 1).
- Various reports have shown the utilization of T7 RNA polymerase for subsequent in vitro transcription of the amplified product and Cas13 based detection.
- coupling of the RT-LAMP amplification, T7- mediated transcription, and Cas13 detection in one pot at relatively high temperature suitable for RT-LAMP amplification is an unmet need.
- thermostable Hi-T7 RNA polymerase which exhibits optimal performance at temperatures close to where both RT-LAMP and thermophilic Cas13 variants are active, was utilized to accomplish this goal.
- crRNAs targeting the highly conserved region in the SARS-CoV-2 N-gene were designed and tested with primer sets previously reported to be highly efficient and specific. Initial screening of these crRNAs and primer sets in two-pots settings, where RT-LAMP was performed first, and the amplified product was used in the second step for T7 RNA polymerase- mediated in-vitro transcription and Cas13-based detection, identified few crRNAs that were highly active ( Figures 3A-3D).
- HheCas13a exhibited strong detection signal in two- pot settings, no significant detection signal was identified in one-pot settings with any crRNA.
- TccCas13a was consistent in specifically and efficiently detecting SARS-CoV-2 target in one-pot with the optimized combination of primers and crRNA. Optimization of the one-pot assay In order to maximize the efficiency of this system, the reaction chemistry was optimized in terms of the type of Bst DNA polymerase used, and the concentrations of Bst DNA polymerase, Hi-T7 RNA polymerase, Mg 2+ and Cas13 RNP in the reaction (Fig.6 and Figs.7A-7D).
- the optimal sensitivity and efficiency of the one-pot detection assay can be achieved if the system is highly tuned with regards to the type and concentration of enzymes used at every step (Fig.6 and Figs.7A-7D).
- the analytical limit of detection (LoD) of the Cas13-based one pot assay was evaluated using synthetic SARS-CoV- 2 RNA as an input.
- the LoD of the one pot assay was estimated to be 20 cp/uL, an improved sensitivity relative to reported Cas13-based one pot assays for SARS-CoV-2 detection (Fig.8) [13]. Because different biochemical reactions perform optimally at different temperatures in the one-pot assay, the performance of the one-pot 143 45497470v1
- thermophilic Cas13-based one-pot assay was tested at different temperatures.
- the optimal temperature as determined by this experiment for the one-pot detection assay was 56°C, with diminished performance at higher or lower temperatures, probably due to the reduced performance of LAMP at lower temperatures, and of the Hi- T7 RNA polymerase at higher temperatures (Figs.15C, 15D).
- Validation of the thermophilic Cas13-based one-pot assay on clinical samples was validated with total RNA extracted from SARS- CoV-2 patient swab samples. Oropharyngeal or nasopharyngeal swab samples were collected from suspected COVID-19 patients. After RNA extraction following the CDC EUA-approved protocol, the samples were confirmed positive for SARS-CoV-2 using RT-qPCR.
- the Cas13-based one- pot assay was first tested on 8 samples (provided in the chart above) with Ct values of 14-27. Using the one-pot Cas13 detection assay, all samples were correctly identified (Fig.9). These results indicate that this newly developed detection system can reliably detect SARS-CoV-2 in clinical samples. Evaluation and clinical validation of OPTIMA-dx assay for SARS- CoV-2 visual detection To provide for large-scale screening during a pandemic, performing diagnostic assays at POC or outside of laboratory settings is important.
- OPTIMA-dx One-pot thermophilic Cas13 and isothermal amplification module for nucleic acid detection.
- the LoD of OPTIMA-dx assay was estimated to be 10 copies (cp)/ ⁇ L, which can be achieved within 45–60 min of reaction time (Fig. 16B).
- OPTIMA-dx was challenged with other common human viruses, including SARS-CoV-1, MERS-CoV, H1N1, HCoV-OC43, HCoV-229E, and HCoV-NL63.
- OPTIMA-dx showed high specificity to SARS-CoV-2, with no cross- reactivity against any of the other tested viruses.
- OPTIMA-dx master mix was assessed. Although the OPTIMA-dx reaction did lose activity after storage for 48 h at 4°C, the detection reaction remained active when stored at –20°C for at least 10 days and after multiple freeze-thaw cycles.
- the one-pot SARS-CoV-2 detection assay demonstrated 94.5% sensitivity and 100% specificity, showing high concordance with the RT-qPCR data (Fig.16C).
- Fig.16C The one-pot SARS-CoV-2 detection assay demonstrated 94.5% sensitivity and 100% specificity, showing high concordance with the RT-qPCR data (Fig.16C).
- OPTIMA-dx detected the RNase P internal control in all tested samples, except one of the negative samples (Fig.16D).
- OPTIMA-dx was utilized for visual detection of SARS- CoV-2 with total RNA extracted from another set of swab samples collected from suspected SARS-CoV-2 patients.
- OPTIMA-dx The validation assays of OPTIMA-dx were conducted using RNA extracted from 45 randomized samples (different from samples used in Fig.16C), 40 positive samples with Ct values ranging between 14–34, and 5 negative samples. A positive OPTIMA-dx signal was detected with all tested samples, with the exception of the negative samples and no template control (NTC) within 1 h. However, samples with Ct values above 30 show a weaker signal compared to samples with Ct values below 30. These results indicated that OPTIMA-dx can reliably detect SARS-CoV- 2 in patient samples within 1 h, with a simple visual readout, for Ct values up to 34. 146 45497470v1
- RNA extraction buffer Sigma Aldrich
- VTM viral transport medium
- sample lysis step was combined with binding and concentration of released RNA using magnetic beads in a single step. This rapid protocol allows both steps (sample lysis and RNA binding to beads) to occur at room temperature in a short period of time (5 minutes). 147 45497470v1
- OPTIMA-dx The performance of the extraction protocol and OPTIMA-dx was tested with oropharyngeal swabs collected from healthy donors and stored in VTM that was spiked with different concentrations of non-infectious SARS-CoV-2 virus particles.
- OPTIMA-dx was able to detect viral load as low as 5000 cp/sample ( ⁇ 50 cp/ ⁇ L of reaction), and RNase P in all tested reactions. Given the encouraging performance of the developed extraction protocol with OPTIMA-dx detection, this assay was conducted on clinical samples.22 individual oropharyngeal swabs collected from COVID-19 patients and 2 oropharyngeal swabs collected from healthy donors stored in VTM were obtained.
- TccCas13a The already established and optimized TccCas13a reaction was used for the detection of SARS-CoV-2 using FAM-labelled RNA reporters, and develop AapCas12b-based detection of RNase P with the use of HEX- labelled ssDNA reporters, which would allow the differentiation between the two fluorescent signals using different detection channels (Fig.17A).
- sgRNAs 3 different AapCas12b single guide RNAs
- the 3 different sgRNAs were used in one-pot, RT-LAMP-coupled AapCas12b RNase P detection reaction using the same OPTIMA-dx reaction components and conditions, and found that all tested sgRNAs showed comparable performance and mediated robust detection as measured from the HEX fluorescence signal (Fig.21A). 149 45497470v1
- sgRNAs 1 and 3 showed faster and more specific signals compared to sgRNA 2. Therefore, sgRNA 1 were selected to develop the one-pot multiplexed OPTIMA-dx reaction.
- sgRNA 1 were selected to develop the one-pot multiplexed OPTIMA-dx reaction.
- the reaction mix contained both RT-LAMP primer sets for the detection of SARS-CoV-2 and RNase P targets and both FAM and HEX reporters.
- SARS-CoV-2 and RNase P were detected in the same reaction using HEX and FAM channels without any fluorescence signal interference from each Cas enzyme’s collateral activity (Fig.17B and Fig.21B).
- the performance of the multiplexed OPTIMA-dx reaction was evaluated for the detection of SARS-CoV-2 and the internal control RNase P on RNA extracted from 14 clinical COVID-19 samples.
- the OPTIMA-dx multiplexed reaction showed an unambiguous positive result for both SARS- CoV-2 and RNase P in all tested clinical samples (Fig.17C).
- the multiplexed detection assay was evaluated on clinical swabs using the simple and quick crude sample extraction method developed above. To this end, 14 oropharyngeal swabs from patients with COVID-19 infection and 2 COVID- 19 negative swabs were obtained. These samples were processed with the extraction procedure and OPTIMA-dx multiplexed detection was performed of both SARS-CoV-2 and RNase P.
- the multiplexed OPTIMA-dx reaction reliably detected both SARS-CoV-2 and RNase P in all SARS-CoV-2 positive samples in 60 min (Fig.17D). Although the OPTIMA-dx master mix showed strong stability when stored at –20°C, it was sought to test whether the OPTIMA-dx reaction components can be freeze-dried, which would further simplify storage and distribution for POC applications. Therefore, OPTIMA-dx reaction was freeze-dried for multiplexed detection and the reaction was tested with the same samples processed with the quick extraction protocol in Fig 17D. The OPTIMA-dx reaction remained functional and was able to detect SARS- 150 45497470v1
- OPTIMA-dx was also run for RNase P in the same samples, resulting in 43 samples testing positive for RNase P out of the 45 samples tested, using the OPTIMA-dx one-pot assay and app. It was concluded that OPTIMA-dx can reach a performance of 95% sensitivity and 100% specificity in patient samples when combined with the mobile app, exhibiting high concordance with RT-qPCR data. Versatility of OPTIMA-dx for pathogen diagnostics The one-pot detection assay of OPTIMA-dx can be adapted for the detection of other pathogens. To demonstrate the versatility of OPTIMA-dx, 151 45497470v1
- RNA virus hepatitis C virus HCV
- TYLCV plant ssDNA virus Tomato yellow leaf curl virus
- OPTIMA-dx detected the virus only in the DNA extracted from infected plants in both DNA dilutions within 1 hour, indicating the high sensitivity and specificity of the OPTIMA-dx platform for efficient detection of plant DNA viruses (Fig.22B). Having established multiplexed detection of SARS-CoV-2 and RNase P with OPTIMA-dx, also shown was the versatility of OPTIMA-dx for multiplexed detection of HCV and RNase P internal control, further demonstrating the capability of OPTIMA-dx for multiplexed detection (Fig.22C). Discussion Initially, CRISPR/Cas diagnostic systems were designed as two-pot assays [4, 5, 14], where reverse transcription and isothermal reactions were performed separately.
- thermophilic Cas13-based one-pot detection assay described herein is the straightforward assay workflow that can be performed without sophisticated equipment or trained personnel. The whole assay can be performed in less than 80 minutes with only minimal equipment or risk of cross-contamination. Frequent, rapid and cost-effective testing without relying on centralized facilities is a key advancement in early screening during pandemic situations [19].
- thermophilic Cas13a enzymes thereby expanding the molecular engineering toolbox of CRISPR systems for RNA substrates; 2) the first report of a one-pot assay using RT-LAMP coupled to Cas13 for specific and sensitive detection of SARS-CoV-2 to facilitate POC applications and limit cross- contamination; 3) the utilization of the identified thermostable Cas13 with a thermostable Cas12b enzyme to develop a one-pot multiplexed detection reaction; 4) the development and use of mobile phone application coupled with the portable, affordable P51 detection to collect and share testing data with central facilities. Since their discovery, Type VI CRISPR Cas13 systems have provided efficient and versatile tools for RNA manipulation [100, 101].
- thermophilic Cas13a enzymes will open diverse biotechnological applications for RNA- guided Cas13a ribonucleases at a broad temperature range and under harsh experimental or environmental conditions, especially if complexed with their corresponding crRNAs.
- Cas13 has recently been gaining interest for therapeutics and disease research, including cancer gene therapy and antiviral therapeutics [83-86].
- in vivo protein stability is important for successful applications [87] and 153 45497470v1
- thermostable enzymes including thermostable Cas9 provide important genome editing applications in thermophiles [91]; specific RNA targeting at elevated temperatures beyond the range of previously reported Cas13 proteins is key to creating new tools for use in industrially important thermophiles, for which no CRISPR-Cas13 system has been reported.
- HheCas13a and TccCas13a are evolutionarily closely related (Fig.1C).
- HheCas13a has been shown to be the only known pre-crRNA processing defective Cas13 [10].
- the data show that both HheCas13a and TccCas13a are incapable of processing pre-crRNA.
- thermophilic Cas13a protein offers a great advance in diagnostics and other applications. Coupling the activity of both thermostable Cas12 and Cas13 enzymes and the specific recognition of correct amplicons by each CRISPR/Cas system, OPTIMA-dx can be used for multiplexed detection of more than one target in a single reaction.
- thermostable Cas13 The multiplexed detection capability of OPTIMA-dx could enable additional nucleic acid detection applications, including detecting different virus variants or different pathogens, such as other common respiratory viruses or bacteria in the same reaction. Future developments will include a visual readout of multiplex detection reactions for simple applications at POC.
- thermostable Cas13 enzymes Two different thermostable Cas13 enzymes were characterized and a thermostable Cas13 was identified that could be adapted for a one-pot RT-LAMP coupled Cas13 detection reaction.
- HheCas13a showed good thermostability and activity in two pot system, good performance was not observed in a one- pot reaction. However, this does not exclude the compatibility of HheCas13a for one-pot detection reactions.
- OPTIMA-dx detection module has several other advantages that make it suited for POC applications.
- OPTIMA-dx demonstrated excellent sensitivity with an LoD of 10 cp/ ⁇ L of synthetic SARS- CoV-2 RNA and can detect samples with Ct values up to 34. Therefore, OPTIMA-dx exhibited robust sensitivity that provides its use for reliable SARS-CoV-2 detection in clinical samples.
- OPTIMA-dx reagents can be lyophilized, which would facilitate pre- assembly of OPTIMA-dx reactions for transportation or long-term storage 155 45497470v1
- OPTIMA-dx detection module does not require RNA extraction and is compatible with simple lysis and extraction methods.
- the ambient- temperature sample lysis and concentration method further increases the simplicity of the assay for POC applications.
- the detection module was also integrated with the portable P51 Molecular Fluorescence Viewer to facilitate sample readout and developed a machine learning module for efficient data collection and sharing of the test results.
- the software provides an additional diagnosis validation and enables fast data sharing, making the entire diagnostic process affordable and accessible to a larger section of society.
- this work provides a thermophilic Cas13a variant and development of a one-pot RT-LAMP-coupled CRISPR-Cas13a assay for sensitive and specific SARS-CoV-2 detection.
- thermophilic Cas13a variants reported in this work have other applications beyond diagnostics, including in RNA knockdown, editing, imaging, and virus interference. This work thus expands the applications of CRISPR- Cas13 systems and offers new possibilities for transcriptome engineering and diagnostics at higher temperatures.
- Example 2 Development of a miniature CRISPR-Cas13 system that facilitates SARS-CoV-2 detection. CRISPR/Cas systems possess great potential for various applications, so there are ongoing efforts to search for, identify, and characterize new Cas effectors to increase utility and develop new tools for in vivo and in vitro applications [48, 49].
- Cas13s for in vivo applications [54-58] Cas13s can be used in diagnostics that exhibit unprecedented sensitivity, specificity, and speed [40, 42-44, 47].
- Different Cas13 variants have been used for nucleic acid detection.
- Cas13a [41, 59], Cas13b [60], and Cas13d [61] exhibit collateral cleavage activities and work for nucleic acid detection.
- This Example expands the existing Cas13-based toolbox for diagnostic applications by identifying and characterizing CRISPR/Cas13 effectors.
- an mCas13 variant was identified, characterized, and its utility for SARS-CoV-2 detection demonstrated.
- Cas13 protein expression and purification To produce the expression plasmid for Cas13 expression and purification, the E. coli codon-optimized Cas13 coding sequence was synthesized (GenScript) de novo and subcloned in frame with His and SUMO tags on the N-terminus into the His6-TwinStrep-SUMO bacterial expression vector (Addgene #115267) using BamHI and NotI (Table 8). Purification of mCas13 protein was performed following the protocol of Kellner et al.
- the mCas13 expression vector was transformed into BL21 E. coli cells.
- Starter cultures were prepared by growing single colonies in LB broth supplemented with 100 ⁇ g/mL ampicillin for 12 h at 37 °C.
- 20 mL of starter culture was used to inoculate 2 L of Terrific Broth medium (TB) (IBI scientific) supplemented with 100 ⁇ g/mL ampicillin for growth at 37 °C until an OD600 of 0.5.
- TB Terrific Broth medium
- Cells were incubated on ice for 30 mins, expression was induced with 0.5 mM IPTG, and cultures were then transferred to 16 °C for overnight expression.
- Cells were harvested by centrifugation for 20 min at 4 °C at 4000 rpm. Cell pellets were resuspended in lysis buffer (50 mM Tris-Cl pH 7.5, 500 mM NaCl, 5% glycerol, 1 mM DTT, EDTA-free protease inhibitor (Roche)) and supplemented with 1 mg/mL lysozyme (L6876, Sigma). Cells were lysed by sonication and clarified by centrifugation at 11,000 rpm for 50 min.
- lysis buffer 50 mM Tris-Cl pH 7.5, 500 mM NaCl, 5% glycerol, 1 mM DTT, EDTA-free protease inhibitor (Roche)
- 1 mg/mL lysozyme L6876, Sigma
- the soluble 6xHis-SUMO-mCas13 in cleared lysate was then purified with an affinity chromatography column (HiTrap Q HP, 5 mL GE Healthcare) (AKTA PURE, GE Healthcare) followed by concurrent removal of the 6xHis-SUMO tag by SUMO protease and overnight dialysis in dialysis buffer.
- Cleaved protein was concentrated to 1.5 mL by Amicon Ultra-15 Centrifugal Filter Units (50 kDa NMWL, UFC905024, Millipore) and further purified via size-exclusion chromatography on a S200 column (GE Healthcare) in gel filtration buffer (50 mM Tris-HCl, 600 mM NaCl, 158 45497470v1
- the N gene target RNA sequences were prepared by in vitro transcription of PCR amplicons containing the T7 promoter sequence using the 2019-nCoV_N_Positive Control plasmid as a PCR template (10006625, IDT).
- RNA Synthesis Kit HiScribe T7 Quick High Yield RNA Synthesis Kit (E2050, NEB).
- the transcripts were purified using Direct-zol RNA Miniprep Kits (R2050, Zymo Research) following the manufacturer's instructions, and the purified RNA was stored at -80 °C.
- mCas13 crRNAs were designed to target the N gene sequence of the SARS-CoV-2 genome.
- templates for in vitro transcription were generated using single-stranded DNA oligos containing a T7 promoter, scaffold, and spacer in reverse complement orientation (IDT), and were then annealed to T7 forward primer in Taq DNA polymerase buffer (Invitrogen). The annealed oligos were then used as templates for in vitro transcription as described above.
- RT-LAMP coupled with T7-mCas13-based detection and LoD range
- control synthetic SARS-CoV-2 viral genomic sequences used in Figure 11 were ordered as synthetic RNA from Twist Bioscience, and were diluted to 10,000 RNA copies/ ⁇ L and used at indicated concentrations to create simulated clinical samples.
- FIP or BIP primers were each designed with the appended T7 promoter sequence at the 5' end of the first half of the primer. Such modification allows the modified primer to integrate the T7 promoter sequence in the LAMP-amplified product for subsequent T7-mediated in vitro transcription. All oligo sequences and substrates are listed in Tables 1, 2 and 7. Screening of crRNAs and reporters and establishing mCas13 collateral detection Activity and collateral assays of Cas13 were performed in 1X cleavage buffer (20 mM HEPES-Na pH 6.8, 50 mM NaCl, 5 mM MgCl2, 1mM DTT) in a 20- ⁇ L final reaction volume.
- 1X cleavage buffer (20 mM HEPES-Na pH 6.8, 50 mM NaCl, 5 mM MgCl2, 1mM DTT
- Cas13 and crRNAs RNPs were first assembled by mixing 500 nM purified Cas13 with 500 nM crRNA (unless otherwise indicated) in 1X cleavage buffer and 20 units RNaseOUT (Invitrogen), followed by incubation at 37 °C for 15 minutes. Next, the assembled RNP was combined on ice with 2 ⁇ L of 500 ng/ ⁇ L in vitro- transcribed target RNA and 250 nM RNA reporter, and reactions incubated for 1 hr at 37 °C (unless otherwise indicated).
- RT-LAMP reactions Reverse transcription and isothermal amplification of target nucleic acids were performed using final concentrations of 1.6 ⁇ M FIP/BIP primers (with the T7 promoter sequence fused to either the FIP or BIP primer), 0.2 ⁇ M F3/B3 primers, and 0.4 ⁇ M LF/LB primers, 1X Isothermal Amplification Buffer (20 mM Tris-HCl, 50 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 2 mM MgSO4, 0.1% Tween 20, pH 8.8) (B0537, NEB), 1.4 mM dNTPs, 8 units of Bst2.0 WarmStart DNA Polymerase (M0538, NEB), 7.5 units of WarmStart
- RNA reporters labeled with the HEX fluorophore were used instead of the FAM fluorophore (Table 3). Collateral cleavage of HEX reporters results in a bright signal that can be easily visualized upon excitation with LED light (Ali et al., 2020). Cas13-based reactions were carried out as described above, with modifications. For each reaction, 1 ⁇ M of HEX reporter (unless otherwise indicated) was used in 20- ⁇ L T7-mCas13 detection reactions. Reactions were incubated at 37 °C for 30 minutes.
- Real-time reverse transcription PCR for detecting positive SARS-CoV2 RNA samples.
- RT-PCR was conducted on extracted RNA samples using the oligonucleotide primer/probe (Integrated DNA Technologies, catalog #10,006,606) and Superscript III one-step RT-PCR system with Platinum Taq Polymerase (catalog #12574 ⁇ 026) following the manufacturer’s protocol. 162 45497470v1
- Table 8 mCas13 protein sequence and tag sequences for protein purification. 6x His affinity tag: residues 5-10; Thrombin site: residues 14-19; Strep-tag II: residues 24-31 and 44-51; SUMO: residues 52-148; mCas13 protein: residues 151-1023. 165 45497470v1
- BLAST Basic Local Alignment Search Tool
- the alignment identified various proteins, including a few uncharacterized putative Cas13 sequences with two predicted RxxxxH (SEQ ID NO:192) motifs of the conserved Cas13 Higher Eukaryotes and Prokaryotes Nucleotide- binding (HEPN) ribonuclease domains [62, 63].
- One small (837 amino acids) candidate showed high similarity (>95% query coverage) to the most efficient Cas13 identified in Xu et al, namely Cas13e.1 [62].
- Further analysis of the metagenomic contigs showed that the putative mCas13 protein has an associated CRISPR array in its immediate vicinity.
- a bacterial expression plasmid for heterologous expression in BL21 Escherichia coli containing the mCas13 sequence was designed and constructed. Subsequently, the protein was produced, and its activity tested in vitro for diagnostic applications. Characterization of CRISPR-mCas13 cis and trans catalytic activities When Cas13/crRNA ribonucleoproteins (RNP) recognize and cleave their target sequence, they also exhibit non-specific, collateral cleavage activity that degrades ssRNAs nearby [63, 64].
- RNP Cas13/crRNA ribonucleoproteins
- collateral activity can be used in nucleic acid detection applications, where a ssRNA probe (reporter) molecule provided in the Cas13 reaction is cleaved by target-dependent Cas13 collateral activity [61].
- the ssRNA reporter can contain a fluorophore linked by a short ssRNA sequence to a quencher, which emits fluorescence after the ssRNA sequence is cleaved, indicating the presence, and therefore the detection, of the target sequence (Fig.10A).
- mCas13 cis and in-trans activities in vitro and to determine the most effective crRNAs to use in the mCas13 SARS-CoV-2- based detection assays
- 10 different crRNAs targeting two different regions in the SARS-CoV-2 nucleocapsid gene (N) were designed and screened.
- the in vitro cleavage activity of mCas13 was first evaluated with 4 different crRNAs targeting single-stranded RNA substrates harboring target sequences complementary to the crRNA spacers.
- mCas13 exhibited different cleavage efficiencies with different crRNAs, with crRNA 4 mediating the highest efficiency relative to other crRNAs and controls (Figure 10L).
- ssRNA target The screening consistently identified crRNA 4 with a significantly higher fluorescence signal relative to the NS crRNA control, indicating the cleavage preference of mCas13 for poly(U) reporter sequences (Figs.10B-10F). Using the poly (U) reporter molecule to screen six more crRNAs targeting different N gene regions indicated that different crRNAs exhibited overall different signal levels. To determine the optimal concentration of mCas13 and crRNA for maximal detection signal, the reaction was performed with titrated mCas13 and crRNA concentrations. It was observed that the optimal concentration of Cas13/crRNA RNP for a true positive signal with no significant signal in NS crRNA control was 500 nM (Fig.10I).
- RT-LAMP coupled with CRISPR-mCas13 for SARS-CoV-2 detection
- pre-amplifying the RNA target of interest is necessary [61].
- RT-LAMP isothermal amplification was chosen because it possesses several advantages over other amplification methods, including high sensitivity, rapid turnaround time, simple operation, and low cost [65].
- primer sets well-established in previous reports to target and amplify conserved regions in the SARS-CoV-2 N gene were used (named here as STOPCovid [36] and DETECTR [37] primer sets).
- these primers were modified by appending a T7 promoter sequence to the 5' end of the first half of either the forward inner primer (FIP) or the backward inner primer (BIP).
- FIP forward inner primer
- BIP backward inner primer
- the T7 promoter sequence integrates into the amplified DNA products, providing a suitable template for the T7 RNA polymerase to transcribe the amplified LAMP product in vitro and generate RNA targets for mCas13 detection (Fig.11A).
- the performance of these modified primers was tested using a synthetic SARS-CoV-2 viral genome at 500 copies/ ⁇ L.
- T7-FIP T7-containing FIP primer
- T7-BIP T7-containing BIP primer
- RT-LAMP pre- amplification of SARS-CoV-2 synthetic RNA using STOPCovid or DETECTR T7-FIP modified primers
- the RT-LAMP products were added to the T7 transcription and mCas13 detection reaction.
- Real-time measurement of the T7-coupled mCas13-based detection indicated robust detection of RT- LAMP product only when using targeting crRNA (crRNA 4) and T7 RNA 169 45497470v1
- both STOPCovid and DETECTR primer sets were assayed to determine the primer set that is most suitable for the mCas13 SARS-CoV-2 detection platform.
- Serial dilutions of the synthetic SARS- CoV-2 viral genome were used as an input for the pre-amplification RT- LAMP reaction. It was observed that both primer sets allowed sensitive detection of the synthetic RNA, but the STOPCovid primers reproducibly detected as few as 4 copies/ ⁇ L viral RNA, compared with 8 copies/ ⁇ L for DETECTR primers (Figs.11C-11D).
- the RT-LAMP pre- amplification step was limited to 35 mins and the mCas13 detection reaction was limited to 20–30 mins, resulting in a total detection time of ⁇ 1 hour or less. Due to its outstanding LoD, the STOPCovid primer set was chosen for the mCas13 detection platform.
- the RT-LAMP coupled CRISPR-mCas13 detection assay is specific for SARS-CoV-2
- SARS-CoV-2- related or non-related viruses including SARS-CoV-1, MERS, TMV, and TuMV, together with SARS-CoV-2. All tested viruses (other than SARS- CoV-2) showed only near-background signals, indicating that the developed assay was highly specific (Fig.11E).
- RNA extraction was validated with total RNA extracted from SARS- CoV-2 patient swab samples. Oropharyngeal or nasopharyngeal swab samples were collected from suspected COVID-19 patients. After RNA extraction following the CDC EUA-approved protocol, the samples were confirmed positive for SARS-CoV-2 using RT-qPCR. The assay was first tested with 17 samples with Ct values of 15–39.
- crRNAs targeting different regions in SARS-CoV-2 were designed.
- One crRNA showed robust collateral activity against poly(U) reporters. Different regions of the crRNA exhibited different tolerances for mismatches, which can be advantageous to designing crRNAs useful for detecting variants that harbor different SNPs.
- the LAMP primers were modified to add the T7 polymerase promoter sequence to permit the T7 RNA polymerase to generate transcripts for mCas13. This modified RT-LAMP enabled the coupling with mCas13 for virus detection, obviating the need for extra steps.
- RT-LAMP coupled with mCas13 exhibited high specificity since sequences of other viruses, including SARS- Co-V1, MERS, TMV, and TuMV, did not trigger the collateral reaction; however, the SARS-CoV2 sequence triggered a strong collateral cleavage reaction and fluorescence.
- the usefulness of this modality (RT-LAMP coupled with mCas13) for SARS-CoV-2 detection was tested and validated in 41 clinical samples. The data showed that mCas13 successfully detected SARS-CoV-2 in clinical samples, exhibiting strong concordance with RT-qPCR.
- a simple LED- based visualizer was employed for straightforward and inexpensive detection 173 45497470v1
- this mCas13-based detection platform enables rapid, accurate, simple, cost- effective, and efficient detection of SARS-CoV-2, and shows potential for POC applications. Due to its miniature size, the mCas13 variant can be used for a variety of in vivo RNA manipulations, including RNA knockdown, editing, splicing regulation, RNA imaging and localization.
- the recently identified compact Cas13, Cas13e.1 shows efficacy against SAR-CoV-2 and influenza A virus, indicating that Cas13 can be useful as an antiviral therapeutic [56, 62].
- the data demonstrate successful identification and characterization of the catalytic activities of a previously unknown/uncharacterized miniature variant of Cas13, and harnessing of its collateral catalytic activities to develop a system for SARS-CoV-2 detection.
- the modality coupling RT-LAMP and mCas13 demonstrates key features, including simplicity, specificity, sensitivity, and portability.
- the readout signal was measured using a low-cost P51 device.
- the P51 device can be paired with a cell phone camera that processes and shares data, facilitating the integration of this modality to large-scale testing. This work illustrates 174 45497470v1
- C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 2016. 353(6299): p. aaf5573. 64. East-Seletsky, A., et al., Two distinct RNase activities of CRISPR- C2c2 enable guide-RNA processing and RNA detection. Nature, 2016.538(7624): p.270-273. 65. Thompson, D. and Y. Lei, Mini review: Recent progress in RT- LAMP enabled COVID-19 detection. Sensors and Actuators Reports, 2020.2(1): p.100017. 66.
- Dao Thi, V.L., et al. A colorimetric RT-LAMP assay and LAMP- sequencing for detecting SARS-CoV-2 RNA in clinical samples. Sci Transl Med, 2020.12(556). 67. Ganguli, A., et al., Rapid Isothermal Amplification and Portable Detection System for SARS-CoV-2. bioRxiv, 2020. 68. Qian, J., et al., An enhanced isothermal amplification assay for viral detection. bioRxiv, 2020. 69. Nagai, K., et al., Diagnostic test accuracy of loop-mediated isothermal amplification assay for Mycobacterium tuberculosis: systematic review and meta-analysis.
- any composition, or subgroup of compositions can be either specifically included for or excluded from use or included in or excluded from a list of compositions.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the method and compositions described herein. Such equivalents are intended to be encompassed by the following claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in 182 45497470v1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2319843.5A GB2622995A (en) | 2021-05-27 | 2022-05-27 | CAS13-based compositions and methods of use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163194099P | 2021-05-27 | 2021-05-27 | |
US63/194,099 | 2021-05-27 | ||
PCT/IB2021/054664 WO2021240443A1 (en) | 2020-05-27 | 2021-05-27 | Iscan: an rt-lamp-coupled crispr-cas module for rapid, sensitive detection of sars-cov-2 |
IBPCT/IB2021/054664 | 2021-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022249152A2 true WO2022249152A2 (en) | 2022-12-01 |
Family
ID=82016483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/055036 WO2022249152A2 (en) | 2021-05-27 | 2022-05-27 | Cas13-based compositions and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2622995A (en) |
WO (1) | WO2022249152A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116083400A (en) * | 2022-12-08 | 2023-05-09 | 广州瑞风生物科技有限公司 | Cas protein truncate, method for constructing same and application thereof |
CN117106101A (en) * | 2023-10-20 | 2023-11-24 | 杭州百裕生物科技有限公司 | Plasmid and ASFV protease inhibitor screening and drug effect evaluation method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019071048A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
-
2022
- 2022-05-27 GB GB2319843.5A patent/GB2622995A/en active Pending
- 2022-05-27 WO PCT/IB2022/055036 patent/WO2022249152A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019071048A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
Non-Patent Citations (115)
Title |
---|
"Biocomputing: Informatics and Genome Projects", 1993, ACADEMIC PRESS |
"Computer Analysis of Sequence Data", 1994, HUMANA PRESS |
"PCR Primer: A Laboratory Manual", 1995, COLD SPRING HARBOR LABORATORY PRESS |
"Sequence Analysis in Molecular Biology", 1987, ACADEMIC PRESS |
A. BISWASR. H. STAALSS. E. MORALESP. C. FINERANC. M. BROWN: "CRISPRDetect: A flexible algorithm to define CRISPR arrays", BMC GENOMICS, vol. 17, 2016, pages 356 |
A. MAHASC. NEAL STEWART, JR.M. M. MAHFOUZ: "Harnessing CRISPR/Cas systems for 713 programmable transcriptional and post-transcriptional regulation", BIOTECHNOL ADV, vol. 714, 2017 |
ABADI, M. ET AL., ARXIV, vol. 1603, 2016, pages 04467 |
ABUDAYYEH, O.O. ET AL.: "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", SCIENCE, vol. 353, no. 6299, 2016, pages aaf5573, XP055407082, DOI: 10.1126/science.aaf5573 |
ACKERMAN, C.M. ET AL.: "Massively multiplexed nucleic acid detection with Casl3", NATURE, vol. 582, no. 7811, 2020, pages 277 - 282, XP037183262, DOI: 10.1038/s41586-020-2279-8 |
ADLI, M., NAT COMMUN., vol. 9, 2018, pages 1911 |
ALI, Z. ET AL.: "iSCAN: An RT-LAMP-coupled CRISPR-Casl2 module for rapid, sensitive detection of SARS-CoV-2", VIRUS RES, vol. 288, 2020, pages 198129, XP086262754, DOI: 10.1016/j.virusres.2020.198129 |
AL-SHAYEB, B. ET AL.: "Clades of huge phages from across Earth's ecosystems", NATURE, vol. 578, no. 7795, 2020, pages 425 - 431, XP037093401, DOI: 10.1038/s41586-020-2007-4 |
AMAN, R. ET AL.: "RNA virus interference via CRISPR/Casl3a system in plants", GENOME BIOL, vol. 19, no. 1, 2018, pages 1, XP055639663, DOI: 10.1186/s13059-017-1381-1 |
AMAN, R., A. MAHAS, M. MAHFOUZ: "Nucleic Acid Detection Using CRISPR/Cas Biosensing Technologies", ACS SYNTH BIOL, 2020 |
AMAN, R.: "Efficient, Rapid, and Sensitive Detection of Plant RNA Viruses With One-Pot RT-RPA-CRISPR/Casl2a Assay", MICROBIOL, vol. 11, 2020, pages 610872 |
ARIZTI-SANZ, J. ET AL.: "Streamlined inactivation, amplification, and Casl3-based detection of SARS-CoV-2", NAT COMMUN, vol. 11, no. 1, 2020, pages 5921 |
BROGAN, D.J.: " A Sensitive, Rapid, and Portable CasRx-based Diagnostic Assay for SARS-CoV-2", MEDRXIV, 2020 |
BROUGHTON, J.P. ET AL.: "CRISPR-Casl2-based detection of SARS-CoV-2", NAT BIOTECHNOL, vol. 38, no. 7, 2020, pages 870 - 874, XP037187541, DOI: 10.1038/s41587-020-0513-4 |
BURMISTRZ, M. ET AL., INT J MOL SCI., vol. 21, no. 3, 2020, pages 1122 |
BURSTEIN, D. ET AL.: "New CRISPR-Cas systems from uncultivated microbes", NATURE, vol. 542, no. 7640, 2017, pages 237 - 241, XP055480893, DOI: 10.1038/nature21059 |
CARILLO, H.LIPMAN, D.: "Computational Molecular Biology", vol. 48, 1988, OXFORD UNIVERSITY PRESS, pages: 1073 |
CHEN, T. ET AL.: "Mxnet: arXiv preprint", ARXIV, vol. 1512, 2015, pages 01274 |
CHOI ET AL., CURR. GENE THER., vol. 5, 2005, pages 299 - 310 |
CHOU, P.H. ET AL.: "Real-time target-specific detection of loop-mediated isothermal amplification for white spot syndrome virus using fluorescence energy transfer-based probes", J VIROL METHODS, vol. 173, no. 1, 2011, pages 67 - 74, XP028174763, DOI: 10.1016/j.jviromet.2011.01.009 |
CORMAN, V.M. ET AL.: "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR", EURO SURVEILL, vol. 25, 2020, pages 3, XP055695049, DOI: 10.2807/1560-7917.ES.2020.25.3.2000045 |
COUVIN, D. ET AL.: "CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced performance and integrates search for Cas proteins", NUCLEIC ACIDS RES, vol. 46, no. W1, 2018, pages W246 - W251 |
COX, D.B.T. ET AL.: "RNA editing with CRISPR-Casl3", SCIENCE, 2017 |
CUI, J.F. LIZ.L. SHI: "Origin and evolution of pathogenic coronaviruses", NAT REV MICROBIOL, vol. 17, no. 3, 2019, pages 181 - 192, XP037065686, DOI: 10.1038/s41579-018-0118-9 |
D. J. BROGAN ET AL.: "A Sensitive, Rapid, and Portable CasRx-based Diagnostic Assay for SARS-CoV-2", MEDRXIV, 2020 |
D. J. BROGAN ET AL.: "Development of a Rapid and Sensitive CasRx-Based Diagnostic Assay for SARS-CoV-2", ACS SENS, vol. 6, 2021, pages 3957 - 3966 |
D. NARASIMHAN ET AL.: "Structural analysis of thermostabilizing mutations of ***e esterase", PROTEIN ENG DES SEL, vol. 23, 2010, pages 537 - 547 |
DAO THI, V.L. ET AL.: "A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples", SCI TRANSL MED, vol. 12, 2020, pages 556 |
E. A. NALEFSKI ET AL.: "Kinetic analysis of Casl2a and Casl3a RNA-Guided nucleases for development of improved CRISPR-Based diagnostics", ISCIENCE, vol. 24, 2021, pages 102996 |
EAST-SELETSKY, A. ET AL.: "RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes", MOL CELL, vol. 66, no. 3, 2017, pages 373 - 383, XP029999996, DOI: 10.1016/j.molcel.2017.04.008 |
EAST-SELETSKY, A. ET AL.: "Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection", NATURE, vol. 538, no. 7624, 2016, pages 270 - 273, XP055719305, DOI: 10.1038/nature19802 |
ESBIN, M.N.: "Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection", RNA, vol. 26, no. 7, 2020, pages 771 - 783, XP055884458, DOI: 1010.1261/rna.076232.120 |
F. PALAZ ET AL.: "CRISPR-Casl3 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research", ACS SYNTH BIOL, vol. 1, 2021, pages 107 |
FOZOUNI, P. ET AL.: "Amplification-free detection of SARS-CoV-2 with CRISPR-Casl3a and mobile phone microscopy", CELL, vol. 184, no. 2, 2021, pages 323 - 333 |
FREIJE, C.A.: "Programmable Inhibition and Detection of RNA Viruses Using Casl3", MOL CELL, vol. 76, no. 5, 2019, pages 826 - 837, XP085939974, DOI: 10.1016/j.molcel.2019.09.013 |
G. J. KNOTTJ. A. DOUDNA: "CRISPR-Cas guides the future of genetic engineering", SCIENCE, vol. 361, 2018, pages 866 - 869 |
GANGULI, A.: "Rapid Isothermal Amplification and Portable Detection System for SARS-CoV-2", BIORXIV, 2020 |
GOOTENBERG, J.S. ET AL.: "Multiplexed and portable nucleic acid detection platform with Casl3, Casl2a, and Csm6", SCIENCE, vol. 360, no. 6387, 2018, pages 439 - 444, XP055538780, DOI: 10.1126/science.aaq0179 |
GOOTENBERG, J.S. ET AL.: "Nucleic acid detection with CRISPR-Cas]3alC2c2", SCIENCE, 2017 |
GOOTENBERG, J.S. ET AL.: "Nucleic acid detection with CRISPR-Casl3a/C2c2", SCIENCE, 2017 |
GOUET, P. ET AL.: "ESPript: analysis of multiple sequence alignments in PostScript", BIOINFORMATICS, vol. 15, no. 4, 1999, pages 305 - 8 |
GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1874 - 1878 |
HOWARD, A.G. ET AL., ARXIV, vol. 1704, 2017, pages 04861 |
I. MOUGIAKOS ET AL.: "Characterizing a thermostable Cas9 for bacterial genome editing and silencing", NAT COMMUN, vol. 8, 2017, pages 1647, XP055536899, DOI: 10.1038/s41467-017-01591-4 |
J. ARIZTI-SANZ ET AL.: "Streamlined inactivation, amplification, and Casl3-based detection 764 of SARS-CoV-2", NAT COMMUN, vol. 11, 2020, pages 5921 |
J. GAOT. LUON. LINS. ZHANGJ. WANG: "A New Tool for CRISPR-Casl3a-Based Cancer Gene Therapy", MOL THER ONCOLYTICS, vol. 19, 2020, pages 79 - 92 |
J. S. CHEN ET AL.: "CRISPR-Casl2a target binding unleashes indiscriminate single-stranded DNase activity", SCIENCE, vol. 360, 2018, pages 436 - 439, XP055615609, DOI: 10.1126/science.aar6245 |
JIA, Y. ET AL.: "Caffe: Convolutional architecture for fast feature embedding", PROCEEDINGS OF THE 22ND ACM INTERNATIONAL CONFERENCE ON MULTIMEDIA, 2014 |
JOUNG, J. ET AL.: "Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing", N ENGL J MED, vol. 383, no. 15, 2020, pages 1492 - 1494 |
JOUNG, J. ET AL.: "Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing", NEW ENGLAND JOURNAL OF MEDICINE, vol. 383, no. 15, 2020, pages 1492 - 1494 |
K. A. CURTIS ET AL.: "A multiplexed RT-LAMP assay for detection of group M HIV-1 in plasma or whole blood", J VIROL METHODS, vol. 255, 2018, pages 91 - 97, XP085361364, DOI: 10.1016/j.jviromet.2018.02.012 |
K. H. OOI: "An engineered CRISPR-Casl2a variant and DNA-RNA hybrid guides enable robust and rapid COVID-19 testing", COMMUN, vol. 12, 2021, pages 1739, XP055896471, DOI: 10.1038/s41467-021-21996-6 |
KELLNER, M.J. ET AL.: "SHERLOCK: nucleic acid detection with CRISPR nucleases", NAT PROTOC, vol. 14, no. 10, 2019, pages 2986 - 3012, XP037003116, DOI: 10.1038/s41596-019-0210-2 |
KELLNER, M.J.: "SHERLOCK: nucleic acid detection with CRISPR nucleases", NATURE PROTOCOLS, vol. 14, no. 10, 2019, pages 2986 - 3012, XP037003116, DOI: 10.1038/s41596-019-0210-2 |
KELLY-CIRINO, C.D. ET AL.: "Importance of diagnostics in epidemic and pandemic preparedness", BMJ GLOB HEALTH, vol. 4, 2019, pages e001179 |
KILIC, T., R. WEISSLEDER,H. LEE: "Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges", ISCIENCE, vol. 23, no. 8, 2020, pages 101406 |
KONERMANN, S. ET AL.: "Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors", CELL, vol. 173, no. 3, 2018, pages 665 - 676, XP055529705, DOI: 10.1016/j.cell.2018.02.033 |
L. B. HARRINGTON ET AL.: "A thermostable Cas9 with increased lifetime in human plasma", NAT COMMUN, vol. 8, 2017, pages 1424, XP055536900, DOI: 10.1038/s41467-017-01408-4 |
L. LI ET AL.: "HOLMESv2: A CRISPR-Casl2b-Assisted Platform for Nucleic Acid Detection and DNA Methylation Quantitation", ACS SYNTH BIOL, vol. 8, 2019, pages 2228 - 2237, XP055690850, DOI: 10.1021/acssynbio.9b00209 |
LARKIN, M.A.: "Clustal W and Clustal X version 2.0", BIOINFORMATICS, vol. 23, no. 21, 2007, pages 2947 - 8 |
LARREMORE, D.B. ET AL.: "Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance", MEDRXIV, 2020 |
LEWIS, GENETIC ENGINEERING NEWS, vol. 12, 1992, pages 1 |
LI, Y. ET AL.: "CRISPR/Cas Systems towards Next-Generation Biosensing", TRENDS BIOTECHNOL, vol. 37, no. 7, 2019, pages 730 - 743, XP085710951, DOI: 10.1016/j.tibtech.2018.12.005 |
LIN, T.-Y. ET AL.: "Focal loss for dense object detection", PROCEEDINGS OF THE IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, 2017 |
LINO CA ET AL., DRUG DELIV., vol. 25, no. 1, 2018, pages 1234 - 1257 |
LIU, T.Y. ET AL., ACCELERATED RNA DETECTION USING TANDEM CRISPR, 2021 |
LIU, T.Y. ET AL.: "Accelerated RNA detection using tandem CRISPR nucleases", MEDRXIV, 2021 |
LOPATO, S. ET AL.: "atSRp30, one of two SF2/ASF-like proteins from Arabidopsis thaliana, regulates splicing of specific plant genes", GENES DEV, vol. 13, no. 8, 1999, pages 987 - 1001, XP002145413 |
M. LOTFIN. REZAEI: "CRISPR/Casl3: A potential therapeutic option of COVID-19", BIOMED PHARMACOTHER, vol. 131, 2020, pages 110738, XP086322133, DOI: 10.1016/j.biopha.2020.110738 |
M. M. KAMINSKIO. O. ABUDAYYEHJ. S. GOOTENBERGF. ZHANGJ. J. COLLINS: "CRISPR- 784 based diagnostics", NAT BIOMED ENG, vol. 5, 2021, pages 643 - 656 |
M. P. TERNS: "CRISPR-Based Technologies: Impact of RNA-Targeting Systems", MOL CELL, vol. 72, 2018, pages 404 - 412, XP085522306, DOI: 10.1016/j.molcel.2018.09.018 |
M. PATCHSUNG ET AL.: "Clinical validation of a Casl3-based assay for the detection of 762 SARS-CoV-2 RNA", NAT BIOMED ENG, vol. 4, 2020, pages 1140 - 1149, XP037313500, DOI: 10.1038/s41551-020-00603-x |
MABEY, D. ET AL.: "Diagnostics for the developing world", NAT REV MICROBIOL, vol. 2, no. 3, 2004, pages 231 - 40 |
MAHAS ET AL., ACS SYNTHETIC BIOLOGY, vol. 10, no. 10, 2021, pages 2541 - 2551 |
MAHAS ET AL.: "Detection of Plant DNA Viruses", VIRUSES, vol. 13, 2021, pages 3 |
MAHAS, A. ET AL.: "LAMP-Coupled CRISPR-Casl2a Module for Rapid and Sensitive Detection of Plant DNA Viruses", VIRUSES, vol. 13, 2021, pages 3 |
MAHAS, A.R. AMANM. MAHFOUZ: "CRISPR-Casl3d mediates robust RNA virus interference in plants", GENOME BIOL, vol. 20, no. 1, 2019, pages 263, XP055871013, DOI: 10.1186/s13059-019-1881-2 |
MARSIC, T. ET AL.: "Vigilant: An Engineered VirD2-Cas9 Complex for Lateral Flow Assay-Based Detection of SARS-CoV2", NANO LETT, 2021 |
MCDERMOTT, J.H. ET AL.: "The rise of point-of-care genetics: how the SARS-CoV-2 pandemic will accelerate adoption of genetic testing in the acute setting", EUR J HUM GENET, 2021 |
MORSHED, M.G.: "Molecular methods used in clinical laboratory: prospects and pitfalls", FEMS IMMUNOL MED MICROBIOL, vol. 49, no. 2, 2007, pages 184 - 91 |
MYHRVOLD, C. ET AL.: "Field-deploy able viral diagnostics using CRISPR-Casl3", SCIENCE, vol. 360, no. 6387, 2018, pages 444 - 448 |
NAGAI, K.: "Diagnostic test accuracy of loop-mediated isothermal amplification assay for Mycobacterium tuberculosis: systematic review and meta-analysis", SCI REP, vol. 6, 2016, pages 39090, XP055911102, DOI: 10.1038/srep39090 |
NAKAMURA, Y. ET AL., NUCL. ACIDS RES., vol. 28, 2000, pages 292 |
NAYEROSSADAT N. ET AL., ADV. BIOMED. RES., vol. 1, 2012, pages 27 |
NEEDELMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
NIEMZ, A.T.M. FERGUSOND.S. BOYLE: "Point-of-care nucleic acid testing for infectious diseases", TRENDS BIOTECHNOL, vol. 29, no. 5, 2011, pages 240 - 50, XP028194817, DOI: 10.1016/j.tibtech.2011.01.007 |
NING, B. ET AL.: "A smartphone-read ultrasensitive and quantitative saliva test for COVID-19", SCI ADV, vol. 7, 2021, pages 2 |
NOTOMI, T.: "Loop-mediated isothermal amplification of DNA", NUCLEIC ACIDS RES, vol. 28, no. 12, 2000, pages E63, XP003018858, DOI: 10.1093/nar/28.12.e63 |
O. O. ABUDAYYEH ET AL.: "RNA targeting with CRISPR-Casl3", NATURE, vol. 550, no. 7675, 2017, pages 280 - 284, XP055529736, DOI: 10.1038/nature24049 |
OBANDE, G.A., K.K. BANGA SINGH: "Current and Future Perspectives on Isothermal Nucleic Acid Amplification Technologies for Diagnosing Infections", INFECT DRUG RESIST, vol. 13, 2020, pages 455 - 483, XP055882804, DOI: 10.2147/IDR.S217571 |
PASZKE, A.: "Pytorch: An imperative style, high-performance deep learning library", ARXIV, vol. 1912, 2019, pages 01703 |
PATCHSUNG, M. ET AL.: "Clinical validation of a Casl3-based assay for the detection of SARS-CoV-2 RNA", NAT BIOMED ENG, vol. 4, no. 12, 2020, pages 1140 - 1149, XP037313500, DOI: 10.1038/s41551-020-00603-x |
PIEPENBURG, O.: "DNA detection using recombination proteins", PLOS BIOL, vol. 4, no. 7, 2006, pages e204, XP002501560, DOI: 10.1371/JOURNAL.PBIO.0040204 |
QIAN, J. ET AL.: "An enhanced isothermal amplification assay for viral detection", BIORXIV, 2020 |
R. E. KONTERMANN: "Strategies for extended serum half-life of protein therapeutics", CURR OPIN BIOTECHNOL, vol. 22, 2011, pages 868 - 876, XP028397475, DOI: 10.1016/j.copbio.2011.06.012 |
RAMACHANDRAN ET AL., ANAL CHEM, vol. 93, no. 20, 2021, pages 7456 - 7464 |
REN ET AL., ARXIV, vol. 1506, 2015, pages 01497 |
S. AGRAWAL: "Rapid detection of SARS-CoV-2 with Casl3", MEDRXIV, 2020 |
SANDLER, M. ET AL.: "Mobilenetv2: Inverted residuals and linear bottlenecks", PROCEEDINGS OF THE IEEE CONFERENCE ON COMPUTER VISION AND PATTERN RECOGNITION, 2018 |
SHMAKOV, S. ET AL.: "Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems", MOL CELL, vol. 60, no. 3, 2015, pages 385 - 97, XP055785070, DOI: 10.1016/j.molcel.2015.10.008 |
SMARGON, A.A.: "Casl3b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28", MOL CELL, vol. 65, no. 4, 2017, pages 618 - 630, XP029924355, DOI: 10.1016/j.molcel.2016.12.023 |
SUN, Y.: "One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPRICas]2a", J TRANSL MED, vol. 19, no. 1, 2021, pages 74 |
T. R. ABBOTT ET AL.: "Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza", CELL, vol. 181, no. 4, 2020, pages 865 - 876, XP055854857, DOI: 10.1016/j.cell.2020.04.020 |
T. Y. LIU ET AL.: "Accelerated RNA detection using tandem CRISPR nucleases", NAT CHEM BIOL, vol. 17, 2021, pages 982 - 988, XP037583616, DOI: 10.1038/s41589-021-00842-2 |
THOMPSON, D.Y. LEI: "Mini review: Recent progress in RT-LAMP enabled COVID-19 detection", SENSORS AND ACTUATORS REPORTS, vol. 2, no. 1, 2020, pages 100017 |
VOGELS, C.B.F. ET AL.: "Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets", NAT MICROBIOL, vol. 5, no. 10, 2020, pages 1299 - 1305, XP037252627, DOI: 10.1038/s41564-020-0761-6 |
WEISS, SCIENCE, vol. 254, 1991, pages 1292 - 1293 |
WONG ET AL., SCIENCE, vol. 228, 1985, pages 810 - 815 |
XU, C. ET AL.: "Novel miniature CRISPR-Casl3 systems from uncultivated microbes effective in degrading SARS-CoV-2 sequences and influenza viruses", RESEARCH SQUARE, 2021, Retrieved from the Internet <URL:https://www.researchsquare.com/article/rs-30924/vl> |
YAN, W.X. ET AL.: "Casl3d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein", MOL CELL, vol. 70, no. 2, 2018, pages 327 - 339, XP055529724, DOI: 10.1016/j.molcel.2018.02.028 |
Z. ALI ET AL.: "iSCAN: An RT-LAMP-coupled CRISPR-Casl2 module for rapid, sensitive detection of SARS-CoV-2", VIRUS RES, vol. 288, pages 198129 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116083400A (en) * | 2022-12-08 | 2023-05-09 | 广州瑞风生物科技有限公司 | Cas protein truncate, method for constructing same and application thereof |
CN116083400B (en) * | 2022-12-08 | 2023-12-12 | 广州瑞风生物科技有限公司 | Cas protein truncate, method for constructing same and application thereof |
CN117106101A (en) * | 2023-10-20 | 2023-11-24 | 杭州百裕生物科技有限公司 | Plasmid and ASFV protease inhibitor screening and drug effect evaluation method |
CN117106101B (en) * | 2023-10-20 | 2024-06-07 | 合肥百裕生物科技有限公司 | Plasmid and ASFV protease inhibitor screening and drug effect evaluation method |
Also Published As
Publication number | Publication date |
---|---|
GB2622995A (en) | 2024-04-03 |
GB202319843D0 (en) | 2024-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Santiago-Frangos et al. | Intrinsic signal amplification by type III CRISPR-Cas systems provides a sequence-specific SARS-CoV-2 diagnostic | |
Batista et al. | Detecting pathogens with Zinc-Finger, TALE and CRISPR-based programmable nucleic acid binding proteins | |
WO2022249152A2 (en) | Cas13-based compositions and methods of use thereof | |
Arizti-Sanz et al. | Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2 | |
Nguyen et al. | A thermostable Cas12b from Brevibacillus leverages one-pot discrimination of SARS-CoV-2 variants of concern | |
Bao et al. | Challenges and opportunities for clustered regularly interspaced short palindromic repeats based molecular biosensing | |
Mahas et al. | Characterization of a thermostable Cas13 enzyme for one-pot detection of SARS-CoV-2 | |
Mahas et al. | A novel miniature CRISPR-Cas13 system for SARS-CoV-2 diagnostics | |
JP7375845B2 (en) | Modified thermostable DNA polymerase | |
US20240076712A1 (en) | Compositions and methods for instant nucleic acid detection | |
Maranhao et al. | An improved and readily available version of Bst DNA Polymerase for LAMP, and applications to COVID-19 diagnostics | |
Huang et al. | dsmCRISPR: Dual synthetic mismatches CRISPR/Cas12a-based detection of SARS-CoV-2 D614G mutation | |
WO2021240443A1 (en) | Iscan: an rt-lamp-coupled crispr-cas module for rapid, sensitive detection of sars-cov-2 | |
WO2020199342A1 (en) | Room temperature nucleic acid amplification reaction | |
Hillary et al. | Potential of CRISPR/Cas system in the diagnosis of COVID-19 infection | |
Nguyen et al. | CRISPR-ENHANCE: An enhanced nucleic acid detection platform using Cas12a | |
Wang et al. | Development of a broadly applicable Cas12a-linked beam unlocking reaction for sensitive and specific detection of respiratory pathogens including SARS-CoV-2 | |
Straiton | CRISPR vs COVID-19: how can gene editing help beat a virus? | |
Brogan et al. | A sensitive, rapid, and portable CasRx-based diagnostic assay for SARS-CoV-2 | |
Arizti-Sanz et al. | Equipment-free detection of SARS-CoV-2 and Variants of Concern using Cas13 | |
Santiago-Frangos et al. | Intrinsic signal amplification by type-III CRISPR-Cas systems provides a sequence-specific viral diagnostic | |
Takahashi et al. | Quick and easy assembly of a one-step qRT-PCR Kit for COVID-19 diagnostics using in-house enzymes | |
US20240191217A1 (en) | Cas10-based assay for nucleic acid detection | |
Lin et al. | Internet of medical things-enabled CRISPR diagnostics for rapid detection of SARS-CoV-2 variants of concern | |
WO2021226278A1 (en) | An ultrasensitive rapid and portable case13d-based diagnostic assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22729303 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 202319843 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20220527 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523451704 Country of ref document: SA |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22729303 Country of ref document: EP Kind code of ref document: A2 |